

**BIV**

2022

# LIFE SCIENCES



OFFICIAL PUBLICATION



SPONSOR



PUBLISHED BY





# LEGAL PROTECTION AT THE MOLECULAR LEVEL.

Protecting innovation in the life sciences requires a different kind of relationship with legal counsel — one shaped by the ability to speak the same language and recognize the full potential of groundbreaking research.

With advanced backgrounds in organic chemistry, molecular biology and immunology among other areas, our intellectual property professionals make the journey from the laboratory to patent protection as seamless as possible. Learn more at [gowlingwlg.com/life-sciences](https://gowlingwlg.com/life-sciences)





# INTERESTED IN SEARCHING, DECODING, & ANALYZING A DATABASE THAT'S 500,000,000 YEARS IN THE MAKING?

We're looking for **engineers**, **developers**, and **data scientists** to work side-by-side with our scientists to build technologies for the development of new medicines. You'll be exploring nature's database of antibodies and leveraging hyperscale computing to help us transform the way new treatments are discovered.

Over the past 10 years, we've developed a full-stack, AI-powered platform that searches, decodes, and analyzes the database of natural immune systems to find antibodies that can be developed as drugs.

## Apply at

[abcellera.com/careers](https://abcellera.com/careers)



It's not a matter of *if*  
we can defeat diabetes.

To us, it's a matter of

# HOW

For over a century, we have remained committed to eradicating diabetes. By supporting innovative thinking, listening to patients and medical experts, and building strong partnerships, we are working towards building healthier communities to defeat chronic disease and improve the lives of Canadians. HOW?

**By donating to the Banting & Best Diabetes Centre**, Canada's leading centre of excellence for innovation in diabetes research, education and clinical care.

**By donating to the Centre Hospitalier de l'Université de Montreal (CHUM)** to help build the first dedicated centre of expertise in diabetes for Quebec.

**By donating to the Réseau d'action en santé cardiovasculaire (RASC)** to help the non-profit create a new interdisciplinary program for obesity prevention and care of obesity.

**By supporting Diabetes Canada's Camp Huronda** in rebuilding their onsite medical facility, the Insul-Inn, so kids living with diabetes can experience camp safely.

**By creating the Novo Nordisk Alberta Diabetes Fund (NOVAD)** to further innovations that can help mitigate the impact of diabetes and obesity in Alberta.

**By launching Cities Changing Diabetes in Mississauga**, our commitment with the city to address systemic issues that contribute to chronic diseases, like diabetes.

**By partnering with the University of Toronto to establish the Novo Nordisk Network for Healthy Populations**, we are committed to discovering new ways to support healthy urban living, drawing on U of T's expertise in public health research.

To find out more about how we are working with communities to overcome diabetes, visit [www.novonordisk.ca](http://www.novonordisk.ca)



# Gandeeva Therapeutics: A differentiated drug discovery platform

## Building better drugs with atomic-resolution imaging and AI

**G**andeeva Therapeutics Founder and CEO Dr. Sriram Subramaniam is globally recognized for his leading contributions in cryo-electron microscopy. In this Q&A, he explains the power of Gandeeva's approach, and how the company differentiates itself as a drug discovery platform.

**LSBC magazine staff:** Tell us about the capabilities of Gandeeva's drug discovery platform.

**Dr. Sriram Subramaniam:** The company is built on series of technical advances in imaging. When I was at the National Institutes of Health, we were developing methods to visualize molecules and viruses and cells with these very powerful methods in imaging using an electron microscope. The main breakthroughs demonstrated that we could use electron beams to visualize protein structures, and small molecule drugs bound to these proteins, at atomic resolution. We could also decipher key conformational changes in these proteins.

Additionally, with artificial intelligence and machine learning, we are seeing this incredibly powerful set of tools emerge in drug development that can enable protein structure prediction and even outcome prediction.

We are leveraging these advances to build what we believe is a differentiated platform deploying a powerful approach to discovering drugs.

**LSBC magazine:** Are there many other companies also leveraging these advances?

**Dr. Subramaniam:** We like to think that we lead the field. The potential of these methods is being gradually recognized. Pharma companies are waking up to the potential of this technology and artificial intelligence. We essentially distill down these methods and technologies to build a pipeline, where we leverage these approaches. The second level of success will really hinge on our unique ability to know how to use these tools, and convert them into products that are superior therapeutics that address unmet needs in the health sector.



**Dr. Sriram Subramaniam**

**LSBC magazine:** What are some of the things you're doing now that are novel and impactful?

**Dr. Subramaniam:** One of the biggest challenges in the treatment of diseases is very often there is resistance to the treatment, there are side effects. Drugs are generally not specifically treating the patient; they treat a version of the disease. What we aim to do is focus on our central belief that medicine should be precision medicine, meaning it should treat the patient. We have an ability to design molecules that have a much lower likelihood of leading to resistance, and are superior in that they have a lower likelihood of being toxic or having late-stage failures. All of those are well-known challenges in the drug development field. Our approach aims to lower those kinds of failures, increase the likelihood of having a molecule that can navigate these hurdles better, and provide superior therapeutic effects for patients.

**LSBC magazine:** What is at the core of Gandeeva's ability to build better drugs?

**Dr. Subramaniam:** The conventional drug discovery approach is typically focused on a single target – a single protein that's maybe defective or not working quite the way that it should. Our approach recognizes that proteins work in communities; they work by communicating with lots of other proteins. By finding molecules, and discovering molecules and drugs that influence those interactions, we seek to achieve the required therapeutic effects. This recognition that

proteins don't work in isolation, and understanding what brings them together and how to influence those interactions, is the core of our approach. We can bring molecules together that might normally not be together, or molecules that may associate only transiently but can be persuaded to be present or interact more strongly with each other.

**LSBC magazine:** Was this approach possible prior to technological advances in imaging and AI?

**Dr. Subramaniam:** We're able to visualize these interactions at atomic resolution. Before, you could make an educated guess. But a lot of where proteins communicate is on the surface, and our ability to look with precision at these interfaces is a game changer. Think of the Gold Rush. Our imaging tools and AI are powerful gold-digging tools. You can't



just dig; knowing where to dig is critical, and you need to have the right kind of tools to dig. That's where we believe we have differentiation in our ability to know where to dig, and then to convert findings


quickly and efficiently into products that address specific therapeutic needs. It's that combination that we believe puts us ahead of anybody else in the field.

**LSBC magazine:** What work will you focus on in the future?

**Dr. Subramaniam:** We want first and foremost to demonstrate our expertise by fighting cancer with superior drugs. But the platform is very, very powerful. We are looking at numerous disease areas where there are unmet needs. In building a company, it's important to have focus. So we've been fairly selective in terms of where we focus our firepower given finite resources. But we see great potential for us to gradually expand over time to take on different areas and different indications.

**CONTENTS**

16



12



**FEATURES**

**12 B.C.'S BOOMING BIO-ECONOMY**

Decades of innovation support success

**16 IN DEPTH: PIETER CULLIS**

A Nobel Prize-worthy lifetime of work

**22 TALENT DEVELOPMENT**

Industry, academia tackle skills shortage

**26 PLATFORM POTENTIAL**

Increasing investment, innovation, odds

**Cementing Canada's leadership 7**

**Nurturing B.C. life sciences 8**

**The future is bright for B.C.'s sector 11**

**A new scientific frontier 21**

**A holistic One Health approach 24**

**24th Annual Life Sciences BC Awards 29**

**Biggest life sciences companies list 32**

**Clinical milestones in life sciences 34**

**Investments in the sector in 2021 35**

**Life sciences companies at a glance 36**

**LSBC membership directory 45**

23



PRESIDENT: Alvin Brouwer  
PUBLISHER AND EDITOR-IN-CHIEF, *BUSINESS IN VANCOUVER*;  
VICE-PRESIDENT, GLACIER MEDIA:  
Kirk LaPointe  
EXECUTIVE EDITOR: Hayley Woodin  
DESIGN: Petra Kaksonen  
PRODUCTION: Rob Benac  
CONTRIBUTORS: Nelson Bennett, Chuck Chiang, Glen Korstrom, Tyler Orton, Albert van Santvoort  
RESEARCHERS: Anna Liczmanska, Albert van Santvoort  
SALES MANAGER: Laura Torrance  
ADVERTISING SALES: Blair Johnston, Corinne Tkachuk, Chris Wilson  
ADMINISTRATOR: Katherine Butler

*Life Sciences* is published by BIV Magazines, a division of BIV Media Group, 303 Fifth Avenue West, Vancouver, B.C. V5Y 1J6, 604-688-2398, fax 604-688-1963, [biv.com](http://biv.com).

Copyright 2022 Business in Vancouver Magazines. All rights reserved. No part of this book may be reproduced in any form or incorporated into any information retrieval system without permission of BIV Magazines. The publishers are not responsible in whole or in part for any errors or omissions in this publication.  
ISSN 1205-5662

Publications Mail Agreement  
No.: 40069240.  
Registration No.: 8876.  
Return undeliverable Canadian addresses to  
Circulation Department:  
303 Fifth Avenue West,  
Vancouver, B.C. V5Y 1J6  
Email: [subscribe@biv.com](mailto:subscribe@biv.com)

Cover: Getty Images/sanjeri

SPONSOR

**Seed<sup>IP</sup>**

PRODUCED BY

**BIV**

BUSINESS INTELLIGENCE FOR B.C.





## CEMENTING CANADA'S GLOBAL LIFE SCIENCES LEADERSHIP

B.C. investment, innovation part of national sector strategy



FRANÇOIS-PHILIPPE  
CHAMPAGNE

Canada's life sciences sector has a long and impressive history of international leadership. From the invention of the world's first pacemaker, to discovering insulin, to first identifying stem cells – the list goes on. We have world-leading health institutions and incubators, recognized leadership in

pharmaceuticals and medical devices and thriving expertise clusters – especially here in B.C.

However, when the COVID-19 pandemic hit, our biopharmaceutical industry was not equipped to provide the large-scale and flexible capacity Canada needed to produce vaccines domestically. As such, our focus was on procuring shots and getting them into Canadian arms. Since that time, thanks to coordinated efforts among so many committed partners, Canada can boast one of the most diverse COVID-19 vaccine portfolios in the world. Not only that, we are leading the world in vaccination rates.

The contributions of B.C.'s life sciences community to these achievements were monumental, like AbCellera Biologics' research on antibodies, and I am most grateful to all our partners here who have helped make this possible.

But the pandemic isn't over yet; in fact, it is anticipated that the frequency of pandemics involving novel pathogens may increase over time. So we know we have more work to do to ensure Canadians remain protected from future health threats.

At the same time, there will likely be an increased global demand for vaccines and therapeutics. There is a real and immediate opportunity here to establish Canada's leadership in the global biopharmaceutical industry and we are seizing it – not only to protect the long-term health and safety of Canadians, but also to create good jobs, and help people around the world. It's a win-win... win!

That's why our government introduced a national Biomanufacturing and Life Sciences Strategy during

the summer of 2021. Developed in partnership with stakeholders, the strategy is actively supporting the growth of a strong, competitive Canadian life sciences sector with cutting-edge biomanufacturing capabilities. We are investing across technology platforms all over the country and ensuring our investments secure access to vaccines, therapies and other innovative medicines for Canadians, but also connect us to global market opportunities.

Only one year in, and we are already seeing fantastic results. We have successfully supported projects that are adding capacity across a range of vaccine platforms and production processes – like RNA vaccine development and production, protein-based vaccines, viral vector manufacturing capacity and new fill-and-finish capabilities.

In all, our government has invested \$1.8 billion in dozens of projects across the country, many of which are in B.C. Just this past March, for example, we provided more than \$90 million to adMare Bioinnovations – a Vancouver non-profit that will use the money to advance new health and pharmaceutical research and development projects, create and scale-up Canadian life sciences companies, support post-doctoral fellowship and undergrad training programs and more.

Because it is crucial to find short-term solutions that also have long-lasting positive impacts, we are ensuring Canada is prepared for future health emergencies, but also going beyond: By supporting cutting-edge research, building critical infrastructure and fostering a lasting talent pipeline, we are establishing a life sciences sector in this country that is strong, growing and world leading.

Brick-by-brick, we are putting foundations back in place that will help Canada remain open to the world during pandemic and non-pandemic times. Together, we are creating a future in which Canada leads in preventing, treating and curing all kinds of illness and disease.

Given how far we have progressed in such a short time, I am confident that made-in-Canada ingenuity and innovation will cement lasting global leadership – with B.C.'s life sciences community helping us lead the way. 🇨🇦

François-Philippe Champagne is the federal minister of innovation, science and industry.

## NURTURING ONE OF CANADA'S FASTEST GROWING LIFE SCIENCES SECTORS

Strategy, investment and collaboration part of plan to support sector



**RAVI KAHLON**

Our province has been through a challenging two years and our life sciences industry has been at the forefront: Virtually every vaccine candidate that reached late-stage development in 2020 used components that were initiated, developed or manufactured in B.C.

I am immensely proud of the hard work done by the incredibly talented people in the B.C. life sciences sector, and the work that continues to be done amid global conflicts and supply chain difficulties.

B.C. is home to one of the fastest growing life sciences sectors in Canada, with more than 2,000 companies employing close to 20,000 British Columbians.

That's why this year, the province committed nearly \$195 million in grant funding to Michael Smith Health Research BC and Genome BC. This funding is another significant step toward solidifying a life sciences hub to support the sector's continued growth, and to anchor B.C. as a global leader in developing new talent, research capacity and life-changing innovation.

That's not all. As outlined in the StrongerBC Economic Plan, clean and inclusive growth are our priorities, and the

province is taking the next steps in developing a life sciences and biomanufacturing strategy. This would nurture continued innovation by leveraging the research capacity of B.C.'s post-secondary institutions, and support employment across the sector.

We know B.C. will have more than one million job openings this decade. Our investments in life sciences will attract, develop and retain the people needed to fill these jobs and bring about the next life-saving innovations in fields such as health care and agriculture by developing clean technology and solutions to mitigate the impacts of climate change.

Collaboration is at the heart of progress in B.C. and the reason we partner with our post-secondary institutions as they train the leaders of tomorrow across the life sciences. B.C. recently contributed \$25 million towards a new five-storey biomedical engineering building with learning spaces and research labs to give University of British Columbia students a new environment in which to hone their skills.

I look forward to watching the B.C. life sciences sector continue to grow and to find more ways to collaborate and create good-paying jobs for British Columbians. We are building a new economy in B.C. and, as the premier says, an economy built for all is an economy built to succeed. 🐾

Ravi Kahlon is B.C.'s minister of jobs, economic recovery and innovation.

COLLABORATION IS AT THE HEART OF PROGRESS IN B.C. AND THE REASON WE PARTNER WITH OUR POST-SECONDARY INSTITUTIONS AS THEY TRAIN THE LEADERS OF TOMORROW ACROSS THE LIFE SCIENCES

**Notch**  
THERAPEUTICS

Working to maximize the benefits  
of cellular immunotherapies.

NotchTX.com





# Accelerating the path to new therapies is ~~un~~attainable

The demands of innovation are evolving ever faster with each new discovery, each new molecule, each new insight. At Cytiva, we evolve with you, helping advance forward with flexible, modular solutions. We shorten the time to the next milestone and to market with automated manufacturing processes.

Together, we'll accelerate brave science.

Learn more at  
**[cytiva.com](https://www.cytiva.com)**

Cytiva and the Drop logo are trademarks of Life Sciences IP Holdings Corp. or an affiliate doing business as Cytiva.  
©2022 Cytiva

For local office contact information, visit [cytiva.com/contact](https://www.cytiva.com/contact)

CY21470-24Aug22-AD



# THANK YOU

Life Sciences BC would like to thank our generous supporters for their ongoing commitment this year.


---

## PLATINUM SPONSORS



---

## GOLD SPONSORS



---

## SILVER SPONSORS



---

## BRONZE SPONSORS

AbbVie  
Amplitude  
Aon  
Aurinia  
Bausch Health  
Boehringer Ingelheim  
British Columbia Securities Commission  
CHÉOS  
Cytiva  
Deloitte

Entrepreneurship@UBC  
EMD Serono  
Evonik  
EY  
Gairdner Foundation  
IRICoR  
LifeLabs  
Lumira Ventures  
Nimbus Synergies  
Novateur Ventures

Novo Nordisk  
Oyen Wiggs  
PwC  
Sanofi  
StarFish Medical  
St Paul's/Providence Health Care  
Takeda  
Xenon

## THE FUTURE IS BRIGHT FOR LIFE SCIENCES IN B.C.

Growing global recognition comes from 30 years of innovation and success



WENDY HURLBURT

What a year it has been for our life sciences community, and Life Sciences BC (LSBC) is honoured to represent and be the voice of the sector in B.C., across Canada and globally. Since the onset of the pandemic, we have seen our community come together like never before and, more than that, be at the forefront

of developing and implementing life-changing solutions to address the unique challenges brought about by COVID-19. I have personally been inspired by the world-class research that has earned our sector international recognition in developing new technologies, treatments and vaccines that are now used around the world – and I know I’m not alone in this. While COVID-19 put B.C. life sciences on the world stage, we have been making meaningful and impactful contributions for the past 30 years. This is something to celebrate: From HIV treatments, to global leadership in antibodies, oncology, precision medicine and nanomedicine, our sector’s history is deeply rooted in scientific expertise, discovery and innovation.

Truly, B.C.’s life sciences ecosystem has never been stronger. We remain home to the fastest growing life sciences sector in Canada, employing close to 20,000 people at over 2,000 companies. The winners of our 24th Annual Life Sciences BC Awards, presented by Farris, have played a crucial role in our sector’s ongoing growth and impact, and the ripple effect globally as a result of these individuals and companies has created life-changing local and global health solutions.

Critical to the sector’s success is the ability to attract, develop and retain talent. As we work together to continue on this upward trajectory, we know there is more work to do. According to BioTalent Canada’s 2021 National Report, Canada’s bio-economy will likely require 65,000 additional workers by 2029. With almost two-thirds of the Canadian

bio-economy located in B.C., Ontario and Alberta, we are committed to doing our part to help improve diversity, create opportunities and foster pathways to help develop a stronger ecosystem of skilled talent in the years to come.

LSBC is in the process of conducting a forward-looking labour market intelligence study to provide a B.C.-focused look at the specific jobs and skills employers are looking for in order to keep up with our dynamic innovation and rapid job growth. The study will help us support our province’s economic recovery and emerging health care needs. We are extremely excited about this project and look forward to leveraging the information and associated recommendations in the months and years to come to ensure our sector continues to thrive, while simultaneously increasing awareness of B.C. as a centre for excellence in life sciences.

On that note, we are so pleased to be an incubator for the many small-to-mid-sized biotech and life sciences companies that call our province “home.” Three of Canada’s largest biotech companies are located in B.C.: Stemcell Technologies, AbCellera Biologics and Aurinia Pharmaceuticals, as well as Canada’s largest medical device company, Starfish Medical. And, there are several more companies blazing their own trails on similar growth trajectories, which collectively raises our profile and attracts more investment. The B.C. government announced in the 2022 budget an investment of almost \$195 million in grant funding to Michael Smith Health Research BC and Genome BC – one example of the government’s commitment to this sector.

The B.C. life sciences sector is on track to become increasingly important to the B.C. and Canadian economies, and now is the time to build an even larger life sciences cluster. We have proven our ability to respond quickly to a pandemic on a global scale, and this has resulted in an unprecedented increase in research funding and scientific discovery.

As we look ahead, I’m confident that the future is bright, and the opportunities endless. If our history has shown us anything, it’s that together, we can create unparalleled opportunities within our sector, while also making a lasting economic impact in our province and beyond. 🐾

Wendy Hurlburt is president and CEO of Life Sciences BC.

WHILE COVID-19 PUT B.C. LIFE SCIENCES ON THE WORLD STAGE, WE HAVE BEEN MAKING MEANINGFUL AND IMPACTFUL CONTRIBUTIONS FOR THE PAST 30 YEARS



# B.C.'S BOOMING BIO-ECONOMY

Decades of ideas and innovation support the evolution and ground-breaking work of the life sciences sector today



PHOTO: GETTY IMAGES/SANJERI

TYLER ORTON

**In sum:** It all started with QLT. Before a group of University of British Columbia (UBC) researchers founded what was then known as Quadra Logic Technologies in the early 1980s, the province's biotech sector was virtually non-existent.

By the end of the 2010s, annual revenue for the B.C. life sciences sector reached \$5.4 billion, according to a 2021 report commissioned by the Greater Vancouver Board of Trade.

And as of 2019, Metro Vancouver was home to 1,300 organizations and 16,000 workers that the BioTalent Canada labour market intelligence firm determined to be part of the country's "bio-economy."

Since the 2019 numbers were calculated, B.C. has seen activity in the sector ramp up with the likes of AbCellera Biologics and Aurinia Pharmaceuticals raising hundreds of millions of dollars after going public in 2020.

But this decades-long journey really only began in earnest when those aforementioned UBC researchers turned their attention to photo-activated drugs and eventually partnered with American Cyanamid to develop the light-activated drug Photofrin in the mid-1980s. But it would not be until a decade later that QLT would reach its zenith, employing nearly 500 workers in B.C.

The company was best known for developing treatments for wet age-related macular degeneration (wet AMD), a leading cause of vision loss for those 50 and older.

Co-founder Julia Levy led the company at its height, with shares reaching \$127 by 1999 before ultimately cratering in the decade to come as legal cases mounted and competitors began entering the market with their own treatments for wet AMD.

As QLT was getting its start in the early 1980s, researcher Allen Eaves was launching the Terry Fox Laboratory before becoming head of hematology at UBC and Vancouver General Hospital in 1985.

To subsidize the increasingly expensive research at the Terry Fox Laboratory, Eaves began selling tissue culture media to labs around the world.

"It just took off, and that was sort of unexpected," Eaves said in 2017. "I didn't know much about business."

Members of the BC Cancer Foundation kept suggesting to



CHRISTENSEN | O'CONNOR  
JOHNSON | KINDNESS

## Protecting the ideas that make the world a better place.

Contributions to medical research, health and pharmaceuticals have led to better health, longer lives and significant discoveries in disease prevention and treatment. COJK intellectual property attorneys partner with innovators in the life sciences to protect, enforce and monetize their cutting-edge achievements. Our depth of experience in science, technology, business, academia and IP law allows us to deliver comprehensive strategies that apply patent, trademark, copyright, litigation and other IP services to protect groundbreaking work in a competitive world.

BIOCHEMISTRY  
NANOTECHNOLOGY  
IMMUNOLOGY  
PHARMACEUTICALS  
MICROBIOLOGY  
MEDICAL DEVICES  
MOLECULAR GENETICS  
COMPUTER SCIENCE

Your Innovation Partners

cojk.com 206.682.8100 info@cojk.com 1201 Third Avenue • Seattle, WA • 98101

## B.C.'S BOOMING BIO-ECONOMY



**Sue Paish leads Canada's Digital Technology Supercluster**

SUBMITTED



**Carl Hansen is CEO of AbCellera**  
**Biologics, which plans to build up a**  
**roster of 1,000 workers in the next**  
**six years** • SUBMITTED

Eaves that he start a company before he finally spun off Stemcell Technologies from the Terry Fox Laboratory in 1993. "They pushed me out a bit," he said, chuckling, "which was good."

Stemcell Technologies specializes in developing the media and processes that make it easier to grow stem cells in research labs around the globe. Or, as founder and CEO Eaves puts it: "We're providing the picks and shovels for the stem-cell gold rush."

By the 2020s, Stemcell had expanded to become the largest biotech company in the province, employing more than 1,000 workers.

Meanwhile, nanomedicine researcher Pieter Cullis had launched his own lab at UBC in the late 1970s. It would eventually deliver critical components used in the messenger RNA (mRNA) COVID-19 vaccines Canadians received from Pfizer.

The lab started with a focus on delivering anti-cancer drugs into the human body with more precision and "having less of them [delivered] to sites that might be vulnerable to the toxic side effects," he says.

After 15 years, the team decided to have a go at delivering much larger particles.

"To give you an idea of the scale, the molecular weight of the common anti-cancer drug would be around about 500 and then the molecular weight of a piece of RNA that we first started to work with was 13,000," Cullis says.

Those mRNA vaccines are dependent on the lipid nanoparticle technology (LNP) developed by Cullis and his team.

The vaccine provides instructions to the cells in the body to make a protein on the surface of the COVID-19 virus. When the body produces that protein, the immune system recognizes it as being foreign and produces a response against it.

The problem is that mRNA is easily broken down by the body and cannot enter cells without help.

But Cullis' research eventually led to the launch of UBC spin-off Acuitas Therapeutics in the 2000s, which developed LNP technology used for gene therapy to treat transthyretin-induced amyloidosis, a rare disease that results in the build-up of proteins in the body's tissue and organs.

Eventually that made-in-B.C. tech was also used as a delivery vehicle that allowed the mRNA to travel through the human body and enter cells unharmed.

Many vaccine skeptics have been taking aim at the speed at which these mRNA vaccines were developed. However, the building blocks behind these vaccines have been in the works for decades.

The pandemic also brought with it a cascading wave of innovation advancements and capital emanating from the West Coast life sciences

WE KNOW THAT WE HAVE  
 GROUND TO MAKE UP IN TERMS OF  
 BIOMANUFACTURING NATIONALLY



**Murray McCutcheon**

Vice-president of corporate development  
 AbCellera

scene.

At the outset of the COVID-19 crisis, Victoria's Starfish Medical was tasked by Ottawa to build 7,500 ventilators for patients across Canada; Richmond's BioLytical Labs developed a COVID-19 antigen test for home use that was recently approved by Health Canada; and the Vancouver-based Digital Technology Supercluster began deploying \$60 million in funding to COVID-19-related projects that launched 16 collaborations between firms like Zymeworks and Variational AI.

"We were, I will say, ahead of the ask. We were developing a pipeline of potential projects that could address specific issues relevant to COVID," Sue Paish, CEO of the Digital Technology Supercluster and former CEO of LifeLabs Medical Laboratory Services, says of the efforts to bring about partnerships across multiple industries prior to Ottawa's request to direct federal funding to the campaign.

The industry also experienced notable acquisitions during this period.

U.S. innovation giant Danaher purchased Vancouver-based Precision Nanosystems Inc. (PNI) in June 2021, just months after Ottawa earmarked \$25 million to help the biotech build a \$50 million biomanufacturing plant. The company has promised to meet its obligations to the federal government regarding future vaccine production.

PNI is best known for producing technology to develop and manufacture genetics medicines that deliver RNA or DNA directly into cells to treat disease at its molecular root cause. PNI specializes in a class of vaccines known as self-amplifying RNA vaccines. These have the potential to create more potent vaccines as they amplify the signal, allowing PNI to manufacture more doses for less volume.

Earlier in the year, Danaher-owned life sciences company Cytiva took aim at another B.C. biotech.

It purchased Burnaby-based Vanrx Pharmaceuticals, which creates robotic machines capable of safely filling liquid drugs into vials, syringes and cartridges. Customers have used





Inside Precision NanoSystems' current Vancouver facilities. The biotech company is in the midst of building a new \$50 million biomanufacturing plant after its acquisition last year by Danaher • CHUNG CHOW

its machines for everything from animal tranquilizers to gene therapies.

Meanwhile, AbCellera Biologics kicked off the stampede of more than a dozen B.C. unicorns – companies valued at US\$1 billion or more – that emerged from the pandemic as investors rushed to pour capital into B.C.'s innovation ecosystem.

The company, best known for specializing in antibody discovery and partnering up with American pharmaceutical giant Eli Lilly on a COVID-19 treatment, raised US\$555 million through a blockbuster initial public offering (IPO) in December 2020.

Within months it made clear its designs on the future, revealing plans for a new 380,000-square-foot headquarters in Vancouver as well as a 130,000-square-foot production facility a few kilometres away in the city's east side. It now plans to build up a roster of 1,000 workers in the next six years – up from the 200 workers it had prior to the IPO.

"We know that we have ground to make up in terms of biomanufacturing nationally, and we're incredibly excited to partner with the Government of Canada in the development of this facility and help us respond faster next time," Murray McCutcheon, AbCellera's vice-president of corporate development, said at the time of the production plant's announcement in 2021.

McCutcheon said a biotech company – one heavily dependent on lab equipment and in-person collaboration – needs to have all

its workers based in Vancouver.

"Historically they've [local university grads] had to seek those opportunities south of the border," says AbCellera CEO Carl Hansen.

"That's one of the reasons it is so important to have these facilities here in Vancouver. You don't want to push people out to the suburbs if you can be anywhere. People want to have that great place to work, the environment, the energy of the city, and they want to be working at the cutting edge of something they think is moving the needle for society." 🐼

---

WE WERE, I WILL SAY, AHEAD OF THE ASK.  
WE WERE DEVELOPING A PIPELINE OF  
POTENTIAL PROJECTS THAT COULD ADDRESS  
SPECIFIC ISSUES RELEVANT TO COVID



**Sue Paish**  
CEO  
Digital Technology Supercluster

## IN DEPTH:

## PIETER CULLIS

A Nobel Prize-worthy lifetime of work

GLEN KORSTROM

Pieter Cullis does not want to jinx his chance of winning a Nobel Prize by discussing the possibility.

The 76-year-old University of British Columbia (UBC) emeritus professor's work was essential in helping Pfizer and BioNTech create a COVID-19 vaccine that has been injected into more than one billion people, perhaps saving millions of lives.

The biochemistry and molecular biology researcher's work with lipid nanoparticles has helped him rack up plenty of awards and gain international recognition.

Last year, he won Thailand's Prince Mahidol Award for medicine, along with colleagues Katalin Kariko and Drew Weissman – a prize that came with a US\$100,000 cheque for the trio.

He was named an officer of the Order of Canada by the end of the year.

Cullis, Germany-based Kariko and U.S.-based Weissman then in January pocketed US\$3 million as part of winning Vietnam's VinFuture Grand Prize. In April, they won a Canada Gairdner International Award, worth \$100,000, and in June, the three won Taiwan's Tang Prize – an honour that came with a cheque for US\$1.7 million, and a US\$350,000 grant for future research.

Tang Prize winners are selected by a committee of internationally renowned experts, and several past recipients have gone on to win Nobel Prizes.

"I'm not going to comment on that," Cullis says when asked how likely it could be for him to win the world's premier award for scientific achievement, which comes with a cheque for 10 million Swedish Krona, or just under US\$1 million.

Kariko and Weissman's expertise was in engineering messenger RNA to be the active ingredient in the vaccine, while Cullis' role was creating the system for getting the vaccine's active ingredient into human cells.

He and his team at UBC have for decades worked with lipid nanoparticles, which are essentially little bubbles that encase

genetic material, cancer drugs, vaccine components or other items, and transport them to specific cells without degradation.

The method is somewhat like a security team transporting an important dignitary through a crowd of rowdy protesters to a key destination.

It is a complex task.

"You have to find a way to have [the encased material] be taken up into a cell, and then into the cytoplasm," Cullis says, referring to the gelatinous liquid that fills the inside of human cells.

"That was the puzzle that we managed to solve."

**RECOGNITION AND AWARDS FOLLOW DECADES OF WORK**

Born in England, Cullis moved to West Vancouver with his parents when he was eight years old.

The West Vancouver High School graduate completed his bachelor's degree, master's degree and a PhD in physics all at UBC before moving on to study at London's Oxford University for a four-year post-doctoral fellowship.


"The time at Oxford was in biochemistry so it was a big switch from physics," he says.

He also briefly conducted research at the University of Utrecht in the Netherlands before returning to UBC as an assistant professor.

Mick Hope, who was a fresh PhD graduate when he met Cullis at the University of Utrecht, says Cullis made an immediate impression.

"He was different from anybody else that I'd come across in the science field up to that point," says Hope, who went on to found several companies with Cullis.

"He was obviously incredibly intelligent, but he was able to focus. He has so many ideas and he knows how to implement



Executives in B.C.'s life sciences sector view Pieter Cullis as one of the most influential people to have worked in the field • CHUNG CHOW

## *Hope, accelerated.*

Explore the new **UBC Micro-certificate in Regulatory Affairs in the Life Sciences**

[atm.med.ubc.ca/regulatory-affairs](http://atm.med.ubc.ca/regulatory-affairs)



THE UNIVERSITY OF BRITISH COLUMBIA


**Academy of Translational Medicine**

Faculty of Medicine





## IN DEPTH: PIETER CULLIS



those ideas, and he doesn't take no for an answer. He's not easily distracted."

Hope says Cullis' incredible work ethic shone through even back at Utrecht.

The two would pull all-nighters because needed equipment was sometimes only available late at night and in the wee hours of the morning.

"We would do a 24-hour shift, and then go back home and sleep, and then come back and do another," Hope says.

The work paid off because it helped the two generate data quickly, publish papers and gain name recognition in the scientific community.

Cullis says he was encouraged to apply for a posting at the University of Nebraska, but he looked at the map and realized that the move would not be the right fit for someone who loves the West Coast, and the ocean.

He considers himself lucky to have won a large grant in the late 1970s, and find an assistant professor job at UBC. He then encouraged Hope to come to Vancouver to join his biochemistry research group.

Lipid nanoparticles were that group's focus from Day 1.

"The basic research I was doing was on the physical properties and functional roles of lipids in biological membranes," Cullis says.

"Biological membranes are pretty important. You have 30 trillion cells in your body, and each one is surrounded by a membrane."

The lipids are about 100 nanometres long (or about 1/100,000th of a millimetre) and are like bubbles, as they are the permeability barriers that separate the insides and outsides

By the mid-1980s, Cullis and his team had devised a way to make lipids using what he calls an external stimuli extrusion technique •

CHUNG CHOW

## HE'S BEEN SORT OF THAT FATHER FIGURE, THAT GODFATHER-FOUNDER



### Ali Tehrani

Venture partner  
Amplitude Ventures

of cells, he explains.

By the mid-1980s, Cullis' team had devised a way to make lipids using what he calls an external stimuli extrusion technique, and they developed a machine to do this work.

They needed no human material to create the lipids.

This led to Cullis in 1985 co-founding his first company, along with Hope and Thomas Madden: Lipex Biomembranes, which marketed a device that Cullis calls the extruder. That venture would later morph into Northern Lipids.

"We found a way to load these things with cancer drugs," Cullis says. "That really triggered the first therapeutic endeavours, which were to try to package up cancer drugs and direct them specifically to tumor sites."

Work with cancer led Cullis, Hope and Madden to co-found the Canadian Liposome Co., which was a subsidiary of Princeton, New Jersey-based The Liposome Co. Inc.

There, the team developed two main drugs – one focused on breast cancer, and another that targeted fungal infections that often affect people undergoing cancer therapies.

A new CEO took charge at The Liposome Co. and demanded that Cullis and his team relocate to New Jersey. That prompted Cullis' team, in 1992, to abandon the Canadian Liposome Co., and set up a new Vancouver-based venture: Inex Pharmaceuticals, which continued to focus on cancer-fighting drugs.

The team then shifted to focus on gene therapies because they found it easier to raise money for that research.

The pivot essentially meant that the company added a line of research that involved putting DNA and RNA compounds in the lipid nanoparticles instead of what had been cancer-fighting compounds, Cullis explains.

It was around 2005 when Cullis embarked on a side project, and helped create UBC's non-profit Centre for Drug Research and Development, which has since rebranded as AdMare Bioinnovations. The organization has helped build Canada's life sciences sector ecosystem.

Cullis' gene-therapy work went into overdrive that same year, when his team linked with Massachusetts-based Alnylam Pharmaceuticals to develop an RNA drug that could suppress a faulty gene in liver cells.

By then, they had left Inex Pharmaceuticals, which had



Cullis completed three degrees at the University of British Columbia. He later returned as an assistant professor • CHUNG CHOW

floundered after a US Food and Drug Administration committee rejected Inex's lead product, Marquibo, for accelerated approval, causing Inex's share price to plunge more than 86 per cent in a day in December 2004.

In 2007, Inex became Tekmira, and then rebranded as Arbutus Bio-pharma Corp. in 2015.

Cullis, Hope and Madden's next venture was Acuitas Therapeutics, which they founded in 2009. It wasn't long before they heard from a researcher at the University of Pennsylvania: Weissman.

He wanted to use Acuitas' system to deliver vaccines to cells, starting with experiments for a vaccine for the Zika virus.

"It turned out that that worked really well," Cullis says.

"The work has not turned into a [Zika virus vaccine] product yet but it will. What the work did was demonstrate that these systems can be very effective vaccines, and it triggered a partnership between Acuitas and BioNTech."

That Acuitas-BioNTech partnership involved Kariko, who is BioNTech's senior vice-president. Work largely focused on creating flu

vaccines, in part because the need was greater and there was more money to be made in developing flu vaccines than Zika virus vaccines, Cullis says.

#### PERFECTLY POISED TO HELP ADDRESS COVID-19 PANDEMIC

When the pandemic hit in early 2020, all efforts pivoted to developing a COVID-19 vaccine.

The timing was impeccable, as Acuitas was perfectly poised to help the world fight off a pandemic that has caused millions of deaths.

"Sometimes you get lucky," Cullis says with a laugh.

The privately owned Acuitas licensed its intellectual property to BioNTech and cashed in on demand for the COVID-19 vaccine.

"Acuitas has done pretty well out of this," Cullis says, without giving specifics on the company's financial situation.

"Obviously, when there's billions of dollars in sales, this is where the lawyers get involved."

Indeed, plenty of lawsuits are yet to be decided.

## Innovative Diagnostics Solutions

Gene Bio Medical is a BC based diagnostic medical device R&D and manufacturing center. We contribute to and improve human health and response capabilities towards a variety of diseases with innovative and industry leading diagnostic testing in healthcare.



604-370-0166 / [info@genebiomedical.com](mailto:info@genebiomedical.com) / [www.genebiomedical.com](http://www.genebiomedical.com)





## IN DEPTH: PIETER CULLIS

Acuitas earlier this year filed a lawsuit against Arbutus – Inex Pharmaceuticals' successor company – and Genevant Sciences GmbH to ward off a legal challenge that Arbutus and Genevant had threatened to launch against Pfizer.

What prompted the suit was that Arbutus and Genevant, in March, filed a lawsuit against Moderna Inc., alleging that patents for its inventions were infringed.

The innovations in question relate to lipid nanoparticle activity. "There's a whole lot of litigation going on – Alnylam has filed lawsuits against Pfizer and Moderna," Cullis adds.

Despite being well past retirement age, Cullis does not foresee himself quitting scientific research.

He simply enjoys it too much.

Cullis no longer teaches at UBC but his status as professor emeritus enables him to keep working at his on-campus lab.

"It's basic research," he says.

"One of the areas I'm really fascinated in is what we call triggered release. With a cancer drug, for example, the problem is that while we can package up these cancer drugs in lipid nanoparticles, we can't get them to come out in the places that we want them to come out, such as the region of a tumor."

He resigned as Acuitas' board chair last year, although he still owns shares in the company.

Cullis has recently shifted his attention to launching NanoVation Therapeutics, which has a platform to enable gene therapy.

Friends say Cullis is not all work, and that he has a fun and playful side.

Hope says Cullis and his team would regularly book venues and hold large parties whenever one of them reached a birthday milestone, such as 40 or 50 years.

The parties got bigger as the years went by, Hope says.

"We'd often have skits," he says. "We actually formed a ballet company called the Royal Lipex Ballet, and we would do dances – all dressed in tutus. So that was kind of quirky."

Jay Kulkarni was a PhD student working under Cullis nearly a decade ago. He tells BIV that he and Cullis would sometimes disagree on the likely outcome of experiments.

Cullis would then suggest that whoever was wrong would owe the other a beer, Kulkarni said.

Cullis confirmed that these bets took place.

"He owes me a lot of beer," Cullis says with a laugh.

B.C. executives across the life sciences sector recognize Cullis as one of the most significant people to have worked in the field.

"He's been sort of that father figure, that godfather-founder," says former Zymeworks CEO Ali Tehrani, who is now a venture partner at Amplitude Ventures.

"I would put him in the top five influential people in the B.C. life sciences sector."

He adds that Cullis has a good chance of eventually winning a Nobel Prize because the impact of his work has been global in scope.

"Nobel Prizes historically have come 20 or 30 years after the fact," Tehrani says. "Given the impact of COVID-19 around the world, I think 20 years from now somebody is going to get it." 🐼



A unique platform led by adMare BioInnovations to connect and collaborate with Canada's life sciences professionals.

Join for free and build your network at [admarebiocommunity.com](https://admarebiocommunity.com)





## A NEW SCIENTIFIC FRONTIER IN PATIENT HEALTH

Exploring the therapeutic potential of phyto-cannabinoids



BARINDER BHULLAR

These are exciting times for cannabinoid researchers inspired by the purpose of using scientific knowledge to foster medical innovation.

The cannabinoid drug market is bringing an exciting and expanded body of promising research to generate safe and effective therapies to benefit global patient health.

The global sales of cannabinoid-based pharmaceuticals were US\$798 million in 2020.

One fascinating area within the cannabinoid world is cannabidiol (CBD) research. The CBD-based pharmaceutical drug market is growing rapidly, powered by increasing scientific research indicating the positive therapeutic potential of CBD actives in various therapeutic areas, including central nervous system diseases, pain disorders, cancer, insomnia, anxiety and more.

This renewed scientific interest in the medical use of cannabinoids and CBD follows the recent discovery of the endocannabinoid system in humans.

The endocannabinoid system is a widespread and complex cell-signalling system that regulates multiple functions, including cognition, sleep, mood, inflammation and pain, and is activated via the CB1 and CB2 receptors in the brain and body, respectively.

CBD has already been used for hundreds of years to treat ailments – it's not a new molecule or ingredient – however, it hasn't been validated clinically or developed as a therapeutic drug at this point, and that needs to change.

While many patients and medical professionals know CBD has potential benefits, medical professionals cannot prescribe it to their patients without clinical validation. Acknowledging the critical opportunities and gaps in

cannabinoid research and data, Vancouver-based Brains Bioceutical has provided evidence to support the efficacy and safety of phyto-cannabinoids in treating major diseases, and has partnered with numerous companies and research institutions, conducting pre-clinical research and clinical trials in various jurisdictions.

Brains Bio, through its wholly-owned subsidiary BSPG Laboratories, produces a natural, non-GMO, hemp-sourced CBD active pharmaceutical ingredient (API) with a purity greater than 99%. It has 0% THC or other prohibited substances and no pesticides, herbicides, heavy metals or radioactivity. This CBD API has been tested by a World Anti-Doping Agency (WADA) lab, NSF and Informed Choice and confirmed for the absence of THC and banned substances.

Brains Bio is involved in 15 clinical trials using CPD API, exploring its effects on treating COVID-19, epilepsy, anxiety, insomnia, opioid addiction and muscle inflammation. Once the results of the clinical trials are available, we will have the research and empirical data needed to solidify our leadership and expertise in using phyto-cannabinoids to treat major diseases and improve patient outcomes.

The team at Brains Bio brings decades of experience in pharmaceuticals, biotechnology and phyto-cannabinoids. This includes in-depth knowledge of capital markets, research and development, clinical trials, product development and the highly complex regulatory landscape governing cannabinoid production worldwide.

It's time for society to accept CBD treatment options without a stigma surrounding cannabis use.

Brains Bioceutical has come into the market to ensure the right product is available to the right researchers. As the medical community becomes more educated on CBD use, I'm confident CBD will continue to blaze a trail to more sustainable and effective treatment. 📌

Barinder Bhullar is senior vice-president, corporate affairs, at Brains Bioceutical.

---

IT'S TIME FOR SOCIETY TO ACCEPT CBD TREATMENT OPTIONS  
WITHOUT A STIGMA SURROUNDING CANNABIS USE

# TALENT DEVELOPMENT

Life sciences industry, academia look to tackle skilled labour shortage head-on

CHUCK CHIANG

**T**he COVID-19 pandemic brought global interest and investment to life sciences – and major contributions towards vaccine research have vaulted B.C.’s life sciences sector into the spotlight. But fame can be a double-edged sword, industry officials say.

The increased attention and investment have also driven a demand for growth – and Canada’s tight market for skilled labour, especially for professionals who are adept at scientific research and scaling up a fledgling business, is now challenging the entire sector.

“We have both a quantity and a quality issue,” says Wendy Hurlburt, president and CEO of Life Sciences BC (LSBC). “There are a lot of jobs being created in the last couple of years ... and in British Columbia, we are blessed with producing talent with very strong technical skills. We are very strong at cross-disciplinary science. But it’s when you get into the commercialization of it where the challenge really emerges.

“You have a gap as it relates to finding talent that can take an innovation and scale it – C-suite executive talent, people with regulatory experience. The gap is: How do you turn this knowledge into a thriving business?”

One company that has seen this shortage first-hand is adMare Bionnovations, which runs an innovation centre in Vancouver aimed squarely at partnering with entrepreneurs and innovators to build life sciences companies, ecosystems and talent in the market.

Anie Perrault, vice-president of public affairs at adMare, says the issue is clear across Canada (the company also runs another innovation centre in Montreal). She notes the company has added significantly to its workforce recently – growing from about 80 to 90 staff members to just short of 130 within a year’s time.

“No doubt, we are in an employee market right now,” Perrault says, adding the advent of remote work-from-home solutions

since the start of the pandemic has meant that Canadian firms are now in open competition for skilled labour with companies from other geographical locations.

“All the life sciences companies are seeking strong talent. The difference is, with adMare, we are looking for people beyond research.... We have corporate services, finance, legal, HR, communications – all the people who surround companies to make them grow.

“One of our advantages is that we offer a lot of flexibility, particularly when it comes to labs,” she says. “Team members can choose between Montreal and Vancouver. It gives PhD students an opportunity to go east or west, and that’s very attractive.”

Not all companies will be so lucky, however. A BioTalent Canada report in 2021 showed the country will add 65,000 new jobs in the sector by 2029 – and many of these jobs that need to be filled will be in B.C., says Simon Fraser University president and vice-chancellor Joy Johnson.

Johnson, who is also a professor of health sciences, notes that academia is keenly aware of the situation and has started efforts to support the life sciences sector with talent in an increasingly urgent manner. Various levels of government are working with schools to boost the number of seats available in B.C. for post-secondary students interested in tech, she says.

Another initiative is increasing the prevalence of “upskilling” – or existing graduates who return to school or expand their studies to develop more capacity to work in the positions being created by industry demand.

“There’s a lot of conversations happening around



AdMare Bionnovations' Vancouver innovation centre is based at the University of British Columbia • SUBMITTED

micro-credentialing,” Johnson says. “So I think it’s promising that there are solutions on the horizon. But we are going to have to move fast if we are going to retain these growing companies in B.C., to ensure they are able to continue to grow and scale-up here.”

Another piece of the puzzle, says LSBC’s Hurlburt, is knowing exactly what the labour demand in the sector looks like, so that stakeholders can collectively look at the data and set priorities based on need.

That is why, she says, the organization announced in July the launch of a labour market intelligence study aimed at providing “a better understanding of the jobs and skills employers are looking for.” It is slated to take 11 months to complete. The study will include five-year demand and supply forecasts, an assessment of factors such as the progress of skills training and recommendations for “sector-led strategies.”

“We have been tracking how much certain companies have been growing,” Hurlburt says. “And we really wanted to do a deeper dive. There have been some national reports on labour markets, but we wanted to take a focus on B.C. specifically – not

only for projections of hiring over the next three-to-five years, but also for knowing what skills will be in the highest demand.

“We need to make sure we have the people – not only in quantity, but also in terms of skilled labour that can actually fill these jobs that are being created.” 🐼

WE ARE GOING TO HAVE TO MOVE FAST IF WE ARE GOING TO RETAIN THESE GROWING COMPANIES IN B.C., TO ENSURE THEY ARE ABLE TO CONTINUE TO GROW AND SCALE-UP HERE



**Joy Johnson**  
President and vice-chancellor  
Simon Fraser University



When it comes to talent, there is both a quality and quantity issue, says Life Sciences BC president and CEO Wendy Hurlburt •

SUBMITTED



Joy Johnson is president and vice-chancellor of Simon Fraser University • SUBMITTED



Anie Perrault is AdMare Bionnovations' vice-president of public affairs • SUBMITTED

## WHY B.C. NEEDS A HOLISTIC ONE HEALTH APPROACH

Policies and practices at the intersection of human, animal and environmental health will net social, environmental and economic benefits



PASCAL SPOTHELFER

Each year, the effects of climate change make the connection between human, animal and environmental health clearer. Equally apparent is the need to examine and understand health impacts from a 'One Health' perspective.

The flooding that occurred in southern British Columbia in late 2021 resulted in the death of over 640,000 animals. An estimated 4,000 tonnes of unharvested vegetables were also lost and three in-land fish farms in the Fraser Valley were severely damaged. This event demonstrated how interconnected crises can be as it displaced nearly 15,000 people from their homes during a time when COVID-19 cases were surging due to the emergence of the Omicron variant.

In early 2022, authorities monitoring the spread of Avian Influenza H5N1 estimated that more than two million farmed birds were impacted by the virus in Canada, significantly impacting animal health and human food supply.

These events underscore the need for a holistic One Health approach in British Columbia. Recognizing that a siloed approach cannot solve complex and multifaceted issues, One Health emphasizes the links between human, animal and environmental health. Interdisciplinary inputs are required to detect, prepare, prevent and respond to these challenges. Policies aligned with the principles of the One Health concept could strengthen the identification, monitoring and prevention of health risks among animals, humans and environments.

One Health efforts are already being championed in British Columbia. Genome BC works closely with government ministries and leading clinical genomics researchers to explore how this approach can advance BC's genomics capacity and benefit the province.

Genomic technology and services are particularly impactful for surveillance. Several Genome BC-funded projects have developed powerful cross-disciplinary surveillance tools that are helping identify and mitigate risks to human health and agriculture. As early as 2015, Genome BC funded a project in partnership with Genome Canada that led to the development of the world's first early warning system for Avian Influenza based on genomics analysis of wetland sediment. The novel

methodology was validated in field studies over two years by demonstrating that the level of detection of Avian Influenza sequences in sediment samples was 37 times more effective for detection compared to previous surveillance programs.

At the outset of the pandemic, Genome BC funded an initiative, led by British Columbia's Centre for Disease Control (BCCDC) Public Health Laboratory, that incorporated genomic analysis into tracking the SARS-CoV-2 virus, adding a critical new dimension to B.C.'s outbreak response. Genome BC also funded a project that surveilled the presence of COVID-19 in farmed mink. This project tracked how the virus impacted mink farms and monitored potential spillover into nearby wild animals. Activities like this help build capacity for future pathogen tracking.

A funding partnership between Genome BC and B.C.'s Ministry of Agriculture and Food further expanded the province's outbreak response capability. Under this partnership, interdisciplinary teams from BCCDC, the University of British Columbia and the Canadian Food Inspection Agency developed sequencing tools to identify strains of norovirus and *Vibrio parahaemolyticus*, a pathogenic bacterium present in marine and coastal environments. These tools change how shellfish-related illness outbreaks and food safety investigations are handled.

Zoonotic diseases like COVID-19 and norovirus are examples of how animal encounters can impact human health. The likelihood of these encounters increases when nature is pushed to its limits. Human activities like resource extraction, agricultural conversion and urbanization impact ecosystems and propel habitat fragmentation – the most significant contributing factor to biodiversity loss. This habitat destruction removes natural buffers, expanding the interface between wildlife and people, where pandemics emerge. This decline in biodiversity reduces the ability of ecosystems to provide essential life-sustaining services – like agricultural productivity, food security, medicines and disease prevention – leading to adverse outcomes for health and well being.

Adopting a One Health approach is essential, as it illuminates the links between healthy ecosystems and human and animal health. Opportunities to expand and accelerate the implementation of One Health through provincial policy are necessary to provide social, environmental and economic benefits to all people in British Columbia. 🐾

Pascal Spothelfer is president and CEO of Genome BC.

ADOPTING A ONE HEALTH APPROACH IS ESSENTIAL, AS IT ILLUMINATES THE LINKS BETWEEN HEALTHY ECOSYSTEMS AND HUMAN AND ANIMAL HEALTH



# SHARED SPACES NEED SHARED SOLUTIONS

'One Health' is a multidisciplinary approach which recognizes that human, animal and environmental health are intricately linked.

Genome British Columbia sees One Health as an important area of focus and funds specific One Health projects to identify risks and find solutions that work for all of us.

 **Genome**  
BritishColumbia

Genomics positively impacts life, every day.

[www.genomebc.ca](http://www.genomebc.ca)



# PLATFORM POTENTIAL

Platform technology and partnerships can increase investment, innovation and research odds



David Main is CEO of Notch Therapeutics, which developed technology to mass-produce immune cells from pluripotent stem cells to treat cancer •

SUBMITTED

NELSON BENNETT

Investing in biotech can be a bit like playing roulette. You can bet a single number – i.e. a bespoke biopharma company focused on a single drug candidate or class of drugs – and hope your number comes up for a 35-to-one payout.

Or you can bet a dozen numbers at a time. The payout is only two-to-one, but the odds of the ball landing on one of 12 numbers out of 38 is a lot higher than landing on one.

From an investor's perspective, life sciences companies with

technology platforms or discovery engines are a bit like betting dozens: The range of possibilities for successful new discoveries and treatments is so much broader.

That may explain why B.C. biotechs that are built around a



WE DO TEND TO PREFER, AND REALLY HONE OUR STRATEGY AROUND, INVESTING IN PLATFORM COMPANIES



#### Nancy Harrison

Venture partner  
Amplitude Ventures

technology platform or discovery engine of some sort have attracted so much attention and capital in recent years.

In 2020, AbCellera Biologics Inc. put its antibody discovery technology into emergency mode, created a “rapid pandemic response platform” and quickly developed monoclonal antibody therapeutics for treating COVID-19, underscoring just how versatile – and nimble – platform technologies can be.

Governments, pharmaceutical companies and investors started throwing money at AbCellera, which raised \$550 million through an initial public offering in 2020 – a significant chunk of the \$2 billion raised on capital markets by B.C. life sciences companies that year. AbCellera is now a \$3 billion company.

Notch Therapeutics, a B.C. biotech with technology that mass-produces immune cells from pluripotent stem cells, last year raised \$85 million in venture capital. Amplitude Ventures, a B.C.-based life sciences-focused venture capital company, was one of the investors.

Nancy Harrison, venture partner at Amplitude Ventures, admits the firm tends to look for biotechs that have technology platforms, like Notch Therapeutics and Zymeworks, another B.C. company in Amplitude’s portfolio.

“We do tend to prefer, and really hone our strategy around, investing in platform companies,” she says. “That’s in order to diversify risk, because they tend to

be game-changing, pivotal investment companies. You can implement a lot of strategies within those.”

Twenty years ago, when Zymeworks was still a startup trying to catch the attention of venture capitalists, one of the things that set it apart was its platform. Zymeworks used molecular modeling to zero-in on proteins and enzymes that could be used to treat a variety of diseases, from cancer to inflammatory diseases.

Ali Tehrani, founder and former CEO of Zymeworks, is now a partner at Amplitude Ventures. He says new technology approaches, like computer modeling, big data and machine learning, opened up whole new avenues for drug discovery.

Many B.C. biotechs today are platform companies, and are as likely to have a founder with a background in computer science, engineering, materials sciences or physics as in biology or medicine.

“We’ve always produced great engineers,” Harrison says. “We’re now at the level of understanding where the engineering approach – with physics, biology and chemistry all coming together – is something we know and can do really well.

“Examples of that are AbCellera, Carl Hansen – engineering physics guy, not a biologist. Precision Nano – engineering physics guy. They were solving a biological problem with physics.”

The platform approach has changed the model for companies looking for partnerships, collaborations and licensing deals, Tehrani says.

“The value proposition has changed,” he says. “Before, it was, ‘Give me a molecule.’ Now it says, ‘Give me access to your engine.’”

A collaboration agreement between Notch Therapeutics and Allogene Therapeutics is a good example. Allogene, a larger company, has complementary technology. Partnering, rather than competing, with Allogene is expected to be mutually beneficial.

“They believe that our platform can help them create a product of interest that they have,” says Notch Therapeutics CEO David Main.

“The vast majority of companies realize that what they’re trying to tackle, they can’t do it all themselves. Allogene’s bringing capital, but also they’re



Nancy Harrison is a venture partner at Amplitude Ventures •

SUBMITTED



## CELEBRATING 30 YEARS OF EXCELLENCE

Join us in looking back on 30 years of innovation as we translate our success in HIV/AIDS towards healthcare sustainability.



@bccentreforexcellence
 @bccfe
 @bccfe
 @bccfe

## PLATFORM POTENTIAL



"The vast majority of companies realize that what they're trying to tackle, they can't do it all themselves," says David Main, CEO of Notch

Therapeutics • SUBMITTED

contributing some of their technology that marries together with our platform very well to make products."

Notch's innovation is technology that can mass-produce immune cells – T cells – from pluripotent stem cells for the treatment of cancer. Currently, creating immune cells from stem cells for cell therapy requires taking cells from a patient or donors, and growing them – something that is time consuming and can sometimes require multiple donors.

"Notch's breakthrough is how to do all of this at a large scale and really dramatically reduce the cost of producing these cells," Main explains.

Some B.C. life sciences companies have merged scientific disciplines that, in the past, might never have crossed paths – cell biology and 3D printing, for example.

Aspect Biosystems uses 3D bioprinting to grow human cells into specialized tissue. Aspect CEO Tamer Mohamed, who has a master's of science degree in electrical and computer engineering, confesses he was a *Star Trek* fan who was inspired by the show's "replicator" which could make things out of thin air.

A pre-clinical stage company, Aspect employs 45 PhD scientists with backgrounds ranging from machine learning and materials science to cell biology.

The company's bioprinting technology can engineer a wide variety of specialized organ tissue – from heart and brain, to liver and pancreas. This diversity has led to numerous collaborations and partnerships, and about \$50 million in funding to date.

"We have over 30 collaborations with research organizations and biopharmas that cover a multitude of different tissues," Mohamed says. "So we're covering almost every tissue of the body through partnership. We know we can't do that ourselves alone."

One of the more promising applications Aspect is developing is the production of specialized pancreas cells – islets – to restore the ability of people with Type 1 diabetes to produce insulin.

It's not a case of growing a new pancreas – just the pancreatic islets, which sense glucose to trigger the release of insulin. The manufactured tissue does not have to be implanted in the pancreas itself – it can be placed elsewhere in the body.

Aspects' ability to bioengineer pancreatic tissue led to a major partnership agreement with Juvenile Diabetes Research Foundation, which is providing funding and research expertise.

"We're working closely with them to accelerate our development at Aspect in terms of creating a functional cure for diabetes," Mohamed says. 🐼



# 24<sup>th</sup> ANNUAL LIFE SCIENCES BC AWARDS

## Building on a foundation of innovation

Life Sciences BC is pleased to announce the well-deserving recipients of the 24th Annual Life Sciences BC Awards, presented by Farris. Each year, these awards recognize the impressive achievements of the many talented individuals, companies and organizations that reflect the thriving life sciences community of British Columbia. Moreover, they truly embody and underscore the full breadth and depth of knowledge that impacts the province's bio-economy, and this awards program celebrates their success in advancing health innovations, and their notable contributions to B.C.'s life sciences ecosystem.

Over the last year, B.C.'s life sciences ecosystem has received worldwide recognition for being at the forefront of the unprecedented challenges in light of the pandemic – and as a result, the sector has never been stronger. In light of this, we also acknowledge the ongoing contributions and efforts of the many individuals, companies and organizations who are helping to propel the sector forward each and every day. As Life Sciences BC looks to continue building upon this globally significant momentum, we invite readers to join us in recognizing the momentous impacts of the 2022 Life Sciences BC Award winners, all of whom set a high standard for excellence and leadership within B.C.'s life sciences ecosystem. Congratulations all!

### 2022 Life Sciences BC Award winners

Dr. Simon Pimstone	Dr. Don Rix Award for Lifetime Achievement in Life Sciences
Dr. Lauchlan Fraser	Genome BC Award for Scientific Excellence
Precision NanoSystems	Deal of the Year
Eupraxia Pharmaceuticals	Emerging Life Sciences Company of the Year Award
Thrive Health	Medical/Digital Technology Company of the Year
adMare BioInnovations	Milton Wong Award for Leadership
Genome BC	Strategic Life Sciences Partner of the Year
Acuitas Therapeutics	Life Sciences Company of the Year
Dr. Pieter Cullis	Global Impact Award



## DR. DON RIX AWARD FOR LIFETIME ACHIEVEMENT IN LIFE SCIENCES

### DR. SIMON PIMSTONE

Dr. Simon Pimstone, MD, PhD, FRCPC, has spent more than 25 years dedicated to life sciences in British Columbia as a clinician, scientist and entrepreneur. He consults at the UBC Cardiology Clinic, where he founded and is a principal investigator of Save BC, a network dedicated to research, treatment and disease prevention in families with early coronary artery disease. Dr. Pimstone has served on the boards of numerous industry and health care associations, and co-chaired the internationally

recognized Science Technology and Innovation Council State of the Nation Report for the federal government. He has helped found multiple life sciences companies, including Xenon Pharmaceuticals, Eupraxia Pharmaceuticals, Alpha9 Theranostics, Kokua Pharmaceuticals and XYON Health. These companies have employed hundreds of people in B.C. and brought approximately \$1 billion into the province through private equity, public equity and strategic business development financing.



## GENOME BC AWARD FOR SCIENTIFIC EXCELLENCE

### DR. LAUCLAN FRASER

Dr. Lauchlan Fraser, an ecosystem ecologist, is a professor and senior Natural Sciences and Engineering Research Council Industrial Research Chair in Ecosystem Reclamation at Thompson Rivers University. Dr. Fraser conducts research on ecosystem reclamation following industrial landscape disturbances, with a particular focus on biodiversity, climate change and grassland ecology. His work has resulted in over 100 peer-reviewed publications in the world's leading scientific journals, and his

expertise is internationally recognized through invitations to serve on national and international boards and committees, including the Genome BC Extractive Industries Sector Steering Committee, BC Technical and Research Committee on Reclamation and the International Association of Vegetation Scientists Global Sponsorship Committee. Dr. Fraser also holds editorial positions with several international scientific journals and serves as a referee for more than 50 journals.



## DEAL OF THE YEAR

### PRECISION NANOSYSTEMS

Precision NanoSystems is a global leader in technologies, solutions and services for the development of lipid nanoparticle-delivered genomic medicines, including mRNA (messenger ribonucleic acid) vaccines and therapeutics. Precision NanoSystems supports (bio)pharma companies that are ushering in the next wave of genomic medicines in infectious

diseases, cancer and rare diseases. The company works with the world's leading drug developers to understand disease and help create the therapeutics and vaccines that will define the future of medicine. Precision NanoSystems' mission is to accelerate the creation of transformative medicine that significantly impacts human wellbeing.



## EMERGING LIFE SCIENCES COMPANY OF THE YEAR AWARD

### EUPRAXIA PHARMACEUTICALS

Eupraxia is a Victoria-based clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to approved drugs. Each product candidate has the potential to address therapeutic areas with high unmet medical need and provide improved patient

benefit by delivering targeted, long-lasting activity with fewer side effects. Eupraxia's lead candidate, EP-104IAR, is currently in Phase 2 development for the treatment of pain due to OA of the knee. In addition to EP-104IAR, Eupraxia is developing a pipeline of earlier-stage long-acting formulations.



## MEDICAL/DIGITAL TECHNOLOGY COMPANY OF THE YEAR

### THRIVE HEALTH

Thrive Health was founded in 2016 by a diverse group of patients, clinicians, researchers, parents and students who came together to help individuals going through complex care journeys. The company's platform enables its customers to configure digital health and wellness solutions to deepen

their relationships with, and empower individuals in, their care. Thrive Health operates across North America, is headquartered in Vancouver and is on a mission to serve as a catalyst in the transformation of access to efficient, effective, empowered care for everyone.

## 24<sup>th</sup> ANNUAL LIFE SCIENCES BC AWARDS



### MILTON WONG AWARD FOR LEADERSHIP ADMARE BIOINNOVATIONS

With a wealth of globally competitive scientific discoveries, Canada is primed to lead the global life sciences community. To make this a reality, the adMare BioInnovations team uses its scientific and commercial expertise, specialized research and development infrastructure and seed

capital to build strong life sciences companies, robust ecosystems and industry-ready talent – and re-invests the company's returns back into the Canadian industry to ensure it is sustained for the long term.



### STRATEGIC LIFE SCIENCES PARTNER OF THE YEAR GENOME BC

Genome BC is a not-for-profit organization supporting world-class genomics research and innovation to grow globally competitive life sciences sectors and deliver sustainable benefits for B.C., Canada and beyond. Over more than 20 years, Genome BC has generated over \$1.27 billion of investment in more than 498 genomics research and innovation projects, including over 1,000 collaborations with partners

across B.C. and internationally. The organization's initiatives are advancing health care, and addressing environmental and natural resource challenges. In addition to scientific programming, Genome BC works to integrate genomics into society by supporting responsible research and innovation, and by fostering an understanding and appreciation of the life sciences.



### LIFE SCIENCES COMPANY OF THE YEAR ACUITAS THERAPEUTICS

Founded in February 2009, Vancouver-based Acuitas Therapeutics is a private biotechnology company that specializes in the development of delivery systems for nucleic acid therapeutics based on lipid nanoparticles. The company partners with pharmaceutical and biotechnology companies and academic institutes to advance nucleic acid therapeutics into clinical trials and the marketplace.

Acuitas Therapeutics' globally respected team works with partners to develop new therapies to address unmet clinical needs. This includes working with Pfizer/BioNTech for the Comirnaty COVID-19 vaccine. Acuitas Therapeutics is focused on the advancement of treatments for HIV/AIDS, cancer, tuberculosis, rabies, malaria and other serious diseases.

### GLOBAL IMPACT AWARD DR. PIETER CULLIS



Dr. Pieter R. Cullis, PhD, FRSC, FNAI(USA), OC, is director of the Nanomedicines Research Group, and a professor in the department of biochemistry and molecular biology at the University of British Columbia (UBC). Dr. Cullis and co-workers have been responsible for fundamental advances in the development of nanomedicines, employing lipid nanoparticle (LNP) technology for cancer therapies, gene therapies and vaccines. This work has contributed to five drugs that have received clinical approval. Dr. Cullis has co-founded 11 biotechnology companies that now employ over 300 people, has published over 350 scientific articles and is an inventor on over 60 patents. He has also co-founded three not-for-profit

enterprises, including the Centre for Drug Research and Development (now adMare BioInnovations) and the NanoMedicines Innovation Network. Dr. Cullis has received numerous awards, including the Order of Canada and the Gairdner International Award. Two recently approved drugs enabled by LNP delivery systems devised by Dr. Cullis and colleagues deserve special emphasis: Onpattro, the first RNAi (ribonucleic acid interference) drug to receive regulatory approval, and Comirnaty, the COVID-19 vaccine developed by Pfizer/BioNTech. Comirnaty has played a major role in containing the global COVID-19 pandemic, with approximately three billion doses administered worldwide in 2021.

## BIGGEST LIFE SCIENCES COMPANIES IN B.C.

RANKED BY | Number of R&amp;D employees in 2021

Rank '22	Company	Top local executive(s)	Areas of research	Ownership	Year founded	No. staff globally '21/'20	No. B.C. staff '21/'20	No. R&D staff '21/'20
1	<b>AbCellera</b> 2215 Yukon St, Vancouver V5V 0A1 P: 604-559-9005 F: NA <a href="http://abcellera.com">abcellera.com</a>	<b>Carl Hansen</b> , president and CEO	AbCellera searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease	Public	2012	386 206	337 195	226 136
2	<b>Stemcell Technologies Inc</b> 1618 Station St, Vancouver V6A 1B6 P: 604-877-0713 F: 800-567-2899 <a href="http://stemcell.com">stemcell.com</a>	<b>Allen Eaves</b> , president and CEO	Provides cell culture media, cell separation tools and accessory reagents for cell biology research, including stem cell biology, regenerative medicine, immunology and cancer research	Privately held	1993	1,520 1,377	1,146 1,057	213 205
3	<b>Kardium Inc</b> 8518 Glenlyon Pky Suite 155, Burnaby V5J 0B6 P: 604-248-8891 F: 604-304-3478 <a href="http://kardium.com">kardium.com</a>	<b>Doug Goertzen</b> , president and COO, <b>Kevin Chaplin</b> , CEO	Cardiovascular	Privately held	2007	190 185	185 180	200 150
4	<b>Zymeworks Inc</b> 114 4th Ave E Suite 800, Vancouver V5T 1G4 P: 604-678-1388 F: 604-737-7071 <a href="http://zymeworks.com">zymeworks.com</a>	<b>Kenneth Galbraith</b> , chair and CEO, <b>Neil Klompas</b> , COO, <b>Chris Astle</b> , senior vice-president and CFO	Antibody and protein therapeutics development with a primary focus in oncology	NYSE:ZYME	2003	462 369	251 212	123 123
5	<b>Amgen British Columbia Inc</b> 7990 Enterprise St, Burnaby V5A 1V7 P: 604-415-1800 F: 604-676-8349 <a href="http://amgen.ca">amgen.ca</a>	NA	Antibody therapeutics for the treatment of cancer, inflammation and infectious diseases	Nasdaq:AMGN	1980	24,000 24,000	110 NA	95 95
6	<b>Xenon Pharmaceuticals Inc</b> 3650 Gilmore Way Suite 200, Burnaby V5G 4W8 P: 604-484-3300 F: 604-484-3450 <a href="http://xenon-pharma.com">xenon-pharma.com</a>	<b>Ian Mortimer</b> , president and CEO	Central nervous system, epilepsy, pain	Nasdaq:XENE	1996	153 129	123 104	90 <sup>2</sup> 73
7	<b>Aurinia Pharmaceuticals Inc</b> 4464 Markham St Suite 1203, Victoria V8Z 7X8 P: 250-708-4272 F: 250-744-2498 <a href="http://auriniapharma.com">auriniapharma.com</a>	<b>Peter Greenleaf</b> , president and CEO	Development of therapeutic drugs for treatment of autoimmune diseases	NA	2013	300 265	NA 55	40 <sup>2</sup> 40 <sup>2</sup>
8	<b>Aspect Biosystems</b> 1781 75th Ave W, Vancouver V6P 6P2 P: 604-263-0502 F: NA <a href="http://aspectbiosystems.com">aspectbiosystems.com</a>	<b>Tamer Mohamed</b> , founder and CEO	Developing bioprinted tissue therapeutics to transform how we treat disease	Privately held	2013	59 36	56 36	38 21
9	<b>Verathon Medical Canada ULC</b> 2227 Douglas Rd, Burnaby V5C 5A9 P: 604-439-3009 F: 604-439-3039 <a href="http://verathon.com">verathon.com</a>	NA	Designs, engineers and manufactures respiratory and surgical devices	Privately held	1984	NA NA	60 83	30 <sup>2</sup> 30 <sup>2</sup>
10	<b>Burrard Pharmaceuticals</b> 2240 Chippendale Rd, West Vancouver V7S 3J5 P: 778-279-3901 F: NA <a href="http://burrardpharma.com">burrardpharma.com</a>	<b>Kayhan Moayeri</b> , CEO	Drug development, manufacturing and formulation	Privately held	2005	NA NA	NA NA	25 <sup>2</sup> 25
11	<b>Artron BioResearch Inc</b> 3938 North Fraser Way, Burnaby V5J 5H6 P: 604-415-9757 F: 604-415-9795 <a href="http://artronbio.com">artronbio.com</a>	<b>Nilgun Demir</b> , vice-president	Antigen and antibody manufacturer	Privately held	2002	NA NA	100 <sup>2</sup> 100	20 <sup>2</sup> 15
12	<b>ABM - Applied Biological Materials Inc</b> 3671 Viking Way Unit 1, Richmond V6V 2J5 P: 604-247-2416 F: 604-247-2414 <a href="http://abmgood.com">abmgood.com</a>	<b>Peter Li</b> , CEO, <b>Ryan Saranchuk</b> , COO	Products span everything from CRISPR gene editing tools and viral vectors/ viruses to the world's largest collection of unique cell lines and the most advanced polymerase chain reaction and next-generation sequencing technologies and services	Privately held	2004	124 123	62 61	18 15
12	<b>Renaissance BioScience Corp</b> 2389 Heath Sciences Mall Suite 410, Vancouver V6T 1Z3 P: 604-822-6499 F: NA <a href="http://renaissancebioscience.com">renaissancebioscience.com</a>	<b>John Husnik</b> , chief scientific officer and CEO, <b>Maurice Boucher</b> , executive chairman, <b>Davona Walton</b> , chief financial officer	Yeast bioengineering company that develops innovative solutions to challenges in multiple industries such as food and beverage, agriculture, human health, aquaculture, and specialty chemicals	Private	2013	NA NA	26 NA	18 NA
14	<b>Response Biomedical Corp</b> 1781 75th Ave W, Vancouver V6P 6P2 P: 604-456-6010 F: 604-456-6066 <a href="http://responsebio.com">responsebio.com</a>	<b>Barbara Kinnaird</b> , CEO	Rapid immunoassay diagnostics for clinical cardiovascular applications, environmental infectious disease testing and bio-threat identification	Privately held	1991	NA NA	65 65	15 <sup>2</sup> 15 <sup>2</sup>
14	<b>SignalChem Biotech Inc</b> 13120 Vanier Pl Suite 110, Richmond V6V 2J2 P: 604-232-4600 F: 604-232-4601 <a href="http://signalchem.com">signalchem.com</a>	<b>Jun Yan</b> , president, <b>Zaihui Zhang</b> , chief scientific officer	Development of innovative cell signalling products	Privately held	2004	100 NA	NA NA	15 15
16	<b>Alectos Therapeutics</b> 8999 Nelson Way, Burnaby V5A 4B5 P: 604-628-7129 F: 604-628-0137 <a href="http://alectos.com">alectos.com</a>	<b>Ernest McEachern</b> , president and CEO	Neuroscience	Privately held	2007	NA NA	12 12	11 11
16	<b>bioLytical Laboratories Inc</b> 13251 Delf Pl Suite 406, Richmond V6V 2A2 P: 866-674-6784 F: NA <a href="http://biolytical.com">biolytical.com</a>	<b>Robert Mackie</b> , CEO, <b>Hans Croukamp</b> , COO	HIV Self Test, HIV1-2 Antibody Test, Multiplex HIV Syphilis Ab Test, COVID-19 Antibody and Antigen Test	Privately held	2002	4 135	95 122	11 19
18	<b>Corcym Canada Corp*</b> 5005 North Fraser Way, Burnaby V5J 5M1 P: 604-412-5650 F: 604-412-5690 <a href="http://corcym.com">corcym.com</a>	<b>Jennifer Arntorp</b> , senior director, operations and site leader	Expertise in the development of heart valve prostheses and repair devices provides users with technologically advanced platforms backed by solid clinical evidence	Privately held		4,000 NA	178 190	10 10
19	<b>Neovasc Inc</b> 13700 Mayfield Pl Unit 2135, Richmond V6V 2J7 P: 604-270-4344 F: 604-270-4384 <a href="http://neovasc.com">neovasc.com</a>	<b>Fred Colen</b> , president and CEO	A specialty medical device company that develops and markets products for the rapidly growing cardiovascular marketplace. Products include Reducer, for the treatment of refractory angina and Tiara™ for the transcatheter treatment of mitral valve disease	Public	2000	NA 71	40 48	6 14

Sources: Interviews with representatives of the above firms and BIV research. NA Not available. NR Not ranked 1-As of February 1, 2022. 2-BIV estimate 3-2020 figure 4-Corcym acquired LivaNova's manufacturing facility in Burnaby in June 2021

Business in Vancouver makes every attempt to publish accurate information in the List, but accuracy cannot be guaranteed. Researched by Anna Liczmanska, [lists@biv.com](mailto:lists@biv.com).



## ZenoTOF 7600 system

Unlock new perspectives for every molecule, in every experiment

EXPLORE THE SYSTEM → [SCIEX.COM/7600](https://sciex.com/7600)





A microscopic view of several virus particles, likely coronaviruses, rendered in a glowing blue color against a dark background. The particles are spherical with a textured surface and numerous small, protruding spikes or receptors. One large particle is in sharp focus in the foreground, while others are blurred in the background.

We **advance** and **protect**  
the world's most valuable  
brands and innovations.

Seed IP Law Group provides Custom Crafted Intellectual Property Solutions™ to clients pursuing patents, trademarks, copyrights and other IP protection. With expertise in cell and molecular biology, immunology, chemistry, biochemistry and pharmacology, Seed IP helps clients patent biotechnology and chemical inventions by offering a team of scientists who also understand the legal and business sides of biotechnology and chemistry.

## 2021

Clinical  
milestones in  
British Columbia's  
life sciences  
sector

Date	Company/organization	Clinical milestone
January	Bold Therapeutics	Bold Therapeutics secures funding to prepare BOLD-100 for COVID-19 clinical trials
January	Kintara Therapeutics	Global Coalition for Adaptive Research, Kazia and Kintara announce commencement of Kazia's Paxalisib and Kintara's VAL-o83 in GBM AGILE trial
January	Neoleukin Therapeutics	Neoleukin Therapeutics receives clinical hold letter from U.S. Food and Drug Administration (FDA) related to chemistry, manufacturing and control (CMC) assay development for NL-201
January	InMed Pharmaceuticals	InMed announces results of second Phase 1 clinical trial of INM-755 CBN Cream in healthy subjects
January	Neoleukin Therapeutics	Neoleukin Therapeutics receives clinical hold letter from U.S. FDA related to CMC assay development for NL-201
January	SaNOTize Research and Development	Covid-busting nasal spray begins U.K. trials January 11
January	Kintara Therapeutics	Kintara announces initiation of patient recruitment for VAL-o83's study arm in the GBM AGILE trial
January	ImmunoFlex	ImmunoFlex receives FLEX 10 product approval from Health Canada
January	Spartan Bioscience	Spartan Bioscience says Health Canada approves rapid COVID-19 test
January	Aurinia Pharmaceuticals	FDA approves Aurinia Pharmaceuticals' Lupkynis (voclosporin) for adult patients with active lupus-nephritis.
February	Kintara Therapeutics	Kintara Therapeutics enrolls final patient in Phase 2 clinical trial of VAL-o83 for recurrent GBM
February	Essa Pharma	Essa Pharma presents favourable initial Phase 1 clinical pharmacology data of EPI-7386 for advanced forms of prostate cancer at the 2021 ASCO Genitourinary Cancers Symposium
March	Johnson & Johnson	Canada authorizes one-shot COVID-19 vaccine from Johnson & Johnson
March	SaNOTize Research and Development	U.K. clinical trial confirms SaNOTize's breakthrough treatment for COVID-19
March	SignalChem Lifesciences	SignalChem enters a clinical trial collaboration with Merck to evaluate the effect of SLC-391 in combination with Keytruda (pembrolizumab) in advanced non-small cell lung cancer
March	API	Newest lupus drug in 60 years discovered in Canada, approved in USA
April	Aurora Biomed	Aurora Biomed announces Health Canada approval for FaStep rapid COVID-19 antigen test
April	Chinook Therapeutics	Chinook Therapeutics announces first patient dosed in Phase 2 affinity basket study of Atrasentan in proteinuric glomerular diseases
April	Aurinia Pharmaceuticals	Aurinia presents data demonstrating Lupkynis (voclosporin) efficacy across lupus nephritis biopsy classes at National Kidney Foundation 2021 spring clinical meetings
April	NervGen Pharma	NervGen Pharma receives ethics approval to initiate Phase 1 clinical trial for NVG-291 remains on track to dose first subjects in Q2 2021

*Note: This list was compiled by Life Sciences BC*

# 2021

Clinical  
milestones in  
British Columbia's  
life sciences  
sector

Date	Company/organization	Clinical milestone
April	Bold Therapeutics	Bold Therapeutics' BOLD-100 effective in vitro against COVID-19 variants
April	bioLytical Laboratories	Biolitycal Laboratories recruiting participants in support of their new one-minute antibody test for COVID-19
April	InMed Pharmaceutical	InMed Pharmaceuticals achieves 2g/L cannabinoid yield with IntegraSyn
April	InMed Pharmaceuticals	InMed Pharmaceuticals submits clinical trial applications to evaluate INM-755 (cannabinol) cream in a Phase 2 trial for epidermolysis bullosa
May	AbCellera	AbCellera-discovered antibody that neutralizes viral variants of COVID-19, LY-CoV1404, enters clinical trials
May	RepliCel Life Sciences	RepliCel announces record year in patents granted
May	Zymeworks	FDA clears Zanidatamab Phase 3 pivotal trial in first line HER2-positive gastroesophageal adenocarcinoma
May	Amgen British Columbia	FDA accepts Amgen's supplemental new drug application for Otezla (apremilast) for adults with mild-to-moderate plaque psoriasis
May	NervGen Pharma	NervGen Pharma announces first subject dosed in Phase 1 clinical trial of NVG-291
May	Bold Therapeutics	FDA grants Bold Therapeutics' BOLD-100 an orphan drug designation in the treatment of gastric cancer
May	Qu Biologics	Qu Biologics files important new IP for the treatment of post-surgical immune dysfunction and prevention of cancer metastasis
May	adMare BioInnovations	AdMare and AazeinTx Inc. sign global exclusive agreement for promising acute asthma treatment (NEO686o)
May	Medicago	COVID vaccine made by Canada's Medicago shows promising results in Phase 2 clinical trial
May	RepliCel Life Sciences	RepliCel launches testing of dermal injector units
May	Zucara Therapeutics	Zucara Therapeutics successfully completes single and multiple ascending dose Phase 1 Trial of ZT-01
June	LifeLabs	LifeLabs completes over two million COVID-19 molecular tests
June	Response Biomedical	Response Biomedical launches COVID-19 (SARS-CoV-2) antigen test for countries accepting CE mark to support the growing demand for testing
June	SaNOtize Research and Development	SaNOtize obtains Health Canada approval to begin enrolment for Phase 3 trials for COVID-19 anti-viral treatment
June	AbCellera	AbCellera responds to future pandemic threat with more than \$190 million Canadian facility
July	Bold Therapeutics	Bold Therapeutics receives FDA clearance to add U.S. sites for Phase 1B/2A trial of BOLD-100 in the treatment of advanced GI cancers
July	ImmunoFlex	ImmunoFlex completes clinical study and submits U.S. and international patent applications
July	Corcym Canada	Corcym announces the first patient enrolled in Mantra study
July	Eupraxia Pharmaceuticals	Eupraxia Pharmaceuticals Inc. announces authorization of clinical trial application for Phase 2 trial of EP-1041AR in osteoarthritis of the knee

*Note: This list was compiled by Life Sciences BC*



## 2021

Clinical  
milestones in  
British Columbia's  
life sciences  
sector

Date	Company/organization	Clinical milestone
July	Pfizer Canada	Pfizer and BioNTech announce collaboration with Biovac to manufacture and distribute COVID-19 vaccine doses within Africa
July	Zucara Therapeutics	Zucara Therapeutics doses first patients in Phase 1B trial of ZT-01
August	AbCellera	Tachyon and AbCellera collaborate to develop novel antibody therapeutic targeting TGF- $\beta$ superfamily member for the treatment of cancer
August	Bausch Health	Health Canada approves Arazlo (Tazarotene) lotion, 0.045%, first such lotion treatment for acne vulgaris
September	Eupraxia Pharmaceuticals	Eupraxia Pharmaceuticals Inc. commences patient screening for its Phase 2 trial for osteoarthritis drug candidate EP-1041AR
September	NervGen Pharma	NervGen Pharma partners with Imeka to use novel neuroimaging technology in clinical trials
September	InMed Pharmaceuticals	InMed Pharmaceuticals announces commencement of Phase 2 clinical trial investigating cannabitol, a rare cannabinoid, in the treatment of epidermolysis bullosa
October	Xenon Pharmaceuticals	Xenon Pharmaceuticals announces positive topline results from Phase 2B 'X-TOLE' clinical trial of XEN1101 for the treatment of focal epilepsy
October	NervGen Pharma	NervGen presents interim Phase 1 clinical trial data for NVG-291 at the American Neurological Association's 146th annual meeting. NVG-291 demonstrated to be well tolerated along with a favourable pharmacokinetic profile
November	Merck Canada	Merck and Ridgeback's Molnupiravir, an oral COVID-19 antiviral medicine, receives first authorization in the world
November	Algernon Pharmaceuticals	Algernon announces positive feedback on its planned Phase 1/2A DMT human stroke study
November	Algernon Pharmaceuticals	Algernon Pharmaceuticals announces positive feedback from U.S. FDA for Phase 1 ifenprodil small cell lung cancer study
November	Medtronic Canada ULC	Medtronic receives Health Canada licence for GI Genius Intelligent Endoscopy Module with artificial intelligence system for colonoscopy
December	Zymeworks	Zymeworks announces second Janssen Bispecific Antibody to begin clinical development utilizing Azymetric and EFECT Therapeutic Platforms
December	Eupraxia Pharmaceuticals	Eupraxia Pharmaceuticals Inc. provides update on its Phase 2 trial for osteoarthritis drug candidate EP-1041AR
December	AbCellera	AbCellera-discovered Bamlanivimab together with Etesevimab authorized as the first and only antibody therapy for emergency use in COVID-19 patients under the age of 12
December	Hoffmann-La Roche	CHMP recommends EU approval of Actemra/RoActemra to treat patients with severe COVID-19
December	GSK	Medicago and GSK announce positive Phase 3 efficacy and safety results for adjuvanted plant-based COVID-19 vaccine candidate
December	UBC Faculty of Medicine	The University of British Columbia launches Canada's first JDRF Centre of Excellence in Type 1 diabetes research
December	Novartis Pharmaceuticals Canada	Novartis presents positive Phase 3 results for Cosentyx in children with active enthesitis-related arthritis and juvenile psoriatic arthritis at ACR 2021
December	Algernon Pharmaceuticals	Algernon Pharmaceuticals completes manufacturing of psychedelic drug DMT, appoints U.K. stroke experts for Phase 2
December	Pfizer Canada	Pfizer and BioNTech receive U.S. FDA emergency use authorization of COVID-19 vaccine booster for individuals 16 years and older
December	Merck Canada	Merck and Ridgeback announce publication of Phase 3 study of Molnupiravir, an investigational oral antiviral COVID-19 treatment, in the New England Journal of Medicine

*Note: This list was compiled by Life Sciences BC*

# 2021

Investments  
into British  
Columbia's life  
sciences sector

Month	Company/organization	Type of investment	Amount (CAD)
January	Bioasis Technologies	Bioasis Technologies Inc. raises \$157,441 through a private investor	\$0.16 million
January	Abdera Therapeutics	Abdera Therapeutics Inc. launches with \$8 million in seed financing	\$8 million
January	Kardium	Kardium has raised US\$115 million in a new financing round	\$146.7 million
February	Precision NanoSystems	Precision NanoSystems Inc. has received a contribution of \$25.1 million through the Strategic Innovation Fund	\$25.1 million
February	RepliCel Life Sciences	RepliCel has closed the first tranche of the investment by MainPointe Pharmaceuticals	\$2.7 million
February	Neovasc	Neovasc announces US\$72 million registered direct offering priced at-the-market	\$91.4 million
February	Notch Therapeutics	Notch Therapeutics closes US\$85 million Series A financing to develop pipeline of renewable stem cell-derived cancer immunotherapies	\$107.9 million
February	InMed Pharmaceuticals	InMed announces closing of US\$4.5 million private placement	\$5.7 million
February	Elevate Farms	Northview LifeSciences announces the closure of a \$1 million investment into Elevate Farms Inc. as part of their \$6.2 million financing	\$1 million
February	Microbion	Microbion has received additional funding from the Cystic Fibrosis Foundation to speed the advancement of inhaled pravibismane for the treatment of cystic fibrosis-related pulmonary infections. This new funding of up to \$1.8 million will directly support toxicology studies	\$1.8 million
February	Essa Pharma	Essa Pharma Inc. completed an underwritten public offering for aggregate gross proceeds of \$149,999,985	\$150 million
February	BriaCell	BriaCell announces closing of US\$25 million public offering	\$31.8 million
March	Government of Canada	Prime Minister Justin Trudeau announced an investment to support more than 100 research projects and almost 1,000 researchers across the country	\$518 million
March	CalciMedica	CalciMedica has secured \$21 million in Series D financing led by Quark Venture LP and GHS Fund (Quark Venture LP and GF Securities), and joined by previous investors Valence Life Sciences and Sanderling Ventures	\$21 million
March	Variantyx	Variantyx secures \$20 million in funding for whole genome sequencing methodology, advanced testing method that diagnoses genetic disorders	\$20 million
March	EyeYon Medical	Global Health Sciences Fund (Quark Venture LP and GF Securities) participates in \$25 million financing for EyeYon Medical's EndoArt clinical trials across three continents	\$25 million
March	UBC Faculty of Medicine	Dr. Brian Kwon and Dr. Babak Shadgan, both faculty members in the department of orthopaedics, have been awarded a US\$3.7 million grant to conduct a clinical trial evaluating a novel implantable biosensor based on near-infrared spectroscopy technology, developed to monitor oxygenation and blood flow status of the injured spinal cord	\$4.6 million
March	Algernon Pharmaceuticals	Algernon Pharmaceuticals received \$2,815,010 from undisclosed investors	\$2.8 million
March	Xenon Pharmaceuticals	Xenon Pharmaceuticals receives \$94,999,998 from Jefferies, Stifel, Nicolaus, William Blair, Needham and Wedbush	\$95 million
March	Eupraxia Pharmaceuticals	Eupraxia Pharmaceuticals raised \$32,345,099 in an initial public offering	\$32.3 million
April	Sanofi	The federal government will spend \$415 million on a partnership with Sanofi Pasteur Ltd. Ontario will contribute \$55 million to the project. Sanofi will spend more than \$455 million, as well as create and maintain 1,225 high-skilled jobs in Canada	\$925 million
April	Province of British Columbia	The B.C. government has launched a new \$10 million program to help small- and medium-sized B.C. manufacturers with commercialization or processing of value-added goods	\$10 million

*Note: this list has been compiled by Life Sciences BC and Novateur Ventures Inc.*

## 2021

Investments  
into British  
Columbia's life  
sciences sector

Month	Company/organization	Type of investment	Amount (CAD)
April	InBC	The B.C. government has introduced legislation to support the operations of InBC Investment Corp., a new \$500-million strategic investment fund	\$500 million
April	iCo Therapeutics	iCo Therapeutics Inc. announces closing of upsized subscription receipt private placement	\$7.3 million
April	Alpha-9 Therapeutics	Alpha-9 Theranostics announces \$11 million Series A financing to advance portfolio of radiotherapeutics and diagnostics	\$11 million
April	RepliCel Life Sciences	RepliCel closes second tranche of strategic investment commitment; this second tranche involved MainPointe's purchase of 1,777,778 common shares issued by RepliCel in exchange for \$1,200,000	\$1.2 million
May	Province of British Columbia	The province is providing the ALS Society of BC with \$2 million for Project Hope to further support patients living with amyotrophic lateral sclerosis (ALS) in British Columbia through research for a cure and clinical trials	\$2 million
May	Resilience Biotechnologies	The federal government today announced a \$200 million investment to help a Mississauga-based company build a plant that can churn out millions of mRNA vaccines	\$200 million
May	Genome BC, BCCDC Foundation	Genome BC, the Michael Smith Foundation for Health Research and the BCCDC Foundation for Public Health have partnered to fund rapid response research initiatives. Nine new projects have been selected for funding, covering a range of priority research areas	\$1.3 million
June	BetterLife Pharma	BetterLife Pharma Inc. raised \$2,324,062 via Research Capital Corp.	\$2.3 million
June	BioVaxys Technology	BioVaxys Technology Corp. raised \$1,626,942	\$1.6 million
June	BriaCell Therapeutics	BriaCell Therapeutics Corp. raised \$22,988,004	\$23 million
June	Clearmind Medicine	Clearmind Medicine Inc. raised \$5,063,857	\$5.1 million
June	Bold Therapeutics	Bold Therapeutics is receiving advisory services and additional research and development funding of up to \$965,000 from the National Research Council of Canada Industrial Research Assistance Program to support the development of BOLD-100 as a novel antiviral, bringing the total project funding to \$1.46 million	\$1.5 million
June	Eupraxia Pharmaceuticals	Eupraxia Pharmaceuticals Inc. announces \$10 million convertible debt agreement with Silicon Valley Bank and conversion of \$6 million pre-initial public offering debt	\$10 million
June	Qu Biologics	Qu Biologics receives additional funding to accelerate clinical development of Qu's first-in-class immunotherapeutic for COVID-19 prevention and treatment. This additional funding brings the total project amount that Qu is receiving from the National Research Council of Canada Industrial Research Assistance Program up to \$2,200,959	\$2.2 million
June	InMed Pharmaceuticals	InMed Pharmaceuticals announces US\$12 million private placement priced at-the-market under Nasdaq rules	\$14.9 million
June	BioTalent Canada	BioTalent Canada announced the continuation of its science and technology internship program – green jobs wage subsidy. This program is funded in part by Natural Resources Canada. The \$3.7 million in funding will help support young, skilled talent.	\$3.7 million
July	Incisive Genetics	Incisive Genetics announces closing of a \$2.5 million seed investment	\$2.5 million
July	XCO Tech	XCO Tech Inc. announced it is receiving advisory services and funding of up to \$1 million from the National Research Council of Canada Industrial Research Assistance Program over three years to advance research and development of embedded AI-based technologies for chronic disease assessment and monitoring.	\$0.3 million
July	Symvivo	Symvivo Corp. receives \$4.6 million support for oral COVID-19 vaccine	\$4.6 million
July	Lumira Ventures	Lumira Ventures closes on US\$255 million of new capital to build transformative health care companies	\$321 million
July	Pfizer	Pfizer authorizes \$1 billion for oral COVID-19 treatment	\$1 billion

Note: this list has been compiled by Life Sciences BC and Novateur Ventures Inc.



# 2021

Investments  
into British  
Columbia's life  
sciences sector

Month	Company/organization	Type of investment	Amount (CAD)
July	BioVaxys Technology	BioVaxys Technology Corp. raised \$838,675	\$0.8 million
July	BioVaxys Technology	BioVaxys Technology Corp. raised \$1,176,880	\$1.2 million
August	Nova Mentis Life Science	Nova Mentis Life Science Corp. raised \$81,657 via Glow LifeTech Corp.	\$0.08 million
September	Alpha Cognition	Alpha Cognition Inc. raised \$9,786,877 via Raymond James and iA Private Wealth Inc.	\$9.8 million
September	Kintara Therapeutics	Kintara Therapeutics raised \$15 million via institutional investors, H.C. Wainwright	\$15 million
October	Algernon Pharmaceuticals	Algernon Pharmaceuticals announces receipt of \$2 million cash refund from Australian research program and files application to list its common shares on Nasdaq capital market	\$2 million
October	GenEp	GenEp, Inc., a biotechnology company developing therapies that address unmet needs in patients with epilepsy, announced the closing of a \$1.45 million seed financing round	\$1.5 million
October	Xenon Pharmaceuticals	Xenon Pharmaceuticals raised \$344,999,993 via Jefferies, SVB Leerink, Stifel, Nicolaus, RBC Capital Markets and Wedbush PacGrow	\$345 million
November	Chinook Therapeutics	Chinook Therapeutics Inc. raised \$183,540,000 via SVB Leerink, Evercore ISI, Oppenheimer, Wedbush PacGrow and H.C. Wainwright	\$183.5 million
November	Eupraxia Pharmaceuticals	Eupraxia Pharmaceuticals Inc. is receiving advisory services and funding up to \$700,000 from the National Research Council of Canada Industrial Research Assistance Program to further develop the company's polymer-based proprietary drug delivery technology	\$0.7 million
November	Variational AI	Variational AI secures US\$3.5 million in seed funding to apply state-of-the-art AI platform to generate novel small molecule therapeutics for drug development	\$4.3 million
November	CHUM	CHUM's <i>Centre d'expertise en diabète</i> received financial support from Novo Nordisk through a \$5 million donation to the Fondation du CHUM	\$5 million
November	Clairvoyant Therapeutics	Clairvoyant Therapeutics secures over \$3 million in seed funding	\$3 million
December	Sonic Incytes	Sonic Incytes successfully completes Series A raise of US\$7.3 million to accelerate Velacur commercialization	\$9.4 million
December	OncoMyx Therapeutics	OncoMyx Therapeutics announced the closing of a \$50 million Series B financing round, co-led by Lumira Ventures and B Capital Group with participation from LYZZ Capital and all Series A investors	\$50 million
December	Virogin Biotech	Virogin Biotech announces closing of US\$127 million in Series D2 financing	\$163 million
<b>TOTAL \$ (CAD)</b>			<b>\$5.1 BILLION</b>

*Note: this list has been compiled by Life Sciences BC and Novateur Ventures Inc.*

# LIFE SCIENCES COMPANIES AT A GLANCE

PLEASE REFER TO <a href="https://lifesciencesbc.ca">LIFESCIENCESBC.CA</a> FOR FURTHER INFORMATION ON THESE COMPANIES			
Company Name	Sector	Area of Expertise	Company Stage
3DQue Systems Inc.	Biotechnology, Medical Technology	3D Bioprinting, Manufacturer, Product Development	Commercial Stage, Private Company
4M BioTech	Biotechnology	Bioproducts	Private Company
AbbVie Corporation	Global Pharmaceutical Corporations, Therapeutics	Autoimmune Diseases, Drug Discovery, Inflammatory Diseases, Mental & Behavioral Health, Neurological Diseases, Oncology, Ophthalmology, Women's Health	Public Company
AbCellera	Biotechnology, Therapeutics	Antibodies, Artificial Intelligence, Autoimmune Diseases, Cardiovascular Disease, Drug Discovery, Infectious Diseases, Inflammatory Diseases, Neurological Diseases, Oncology, Ophthalmology, Therapeutics	Public Company
Abdera Therapeutics	Biotechnology, Therapeutics	Therapeutics	Clinical Stage
ABOzymes Biomedical Inc.	Biotechnology, Medical Technology	Antibodies, Antigen, Therapeutics	Discovery Preclinical studies, Seed Stage
Acuitas Therapeutics	Biotechnology, Medical Technology, Therapeutics	mRNA, Nanomedicine, Therapeutics	Commercial Stage, Private Company
adMare BioInnovations	Accelerators & Incubators, Biotechnology, Investors, Not-for-profit, Therapeutics	Antibodies, Antigen, Autoimmune Diseases, Cardiovascular Disease, Cellular Medicine, Drug Delivery, Drug Discovery, Gene Therapy, Genomics, Immune Therapy, Inflammatory Diseases, Metabolic Diseases, Microbiome, mRNA, Nanomedicine, Neurological Diseases, Oncology, Ophthalmology, Pediatrics, Radio Pharmaceuticals, Regenerative Medicine, Regulatory, Teaching and Training, Therapeutics	Discovery Preclinical studies, Pre-Seed stage, Seed Stage, Start-up
Aequus Pharmaceuticals	Biotechnology, Therapeutics	Neurological Diseases, Ophthalmology	Commercial Stage, Public Company
Alectos Therapeutics	Biotechnology, Therapeutics	Drug Discovery, Neurological Diseases, Therapeutics	Discovery Preclinical studies, Private Company
Algernon Pharmaceuticals	Biotechnology, Global Pharmaceutical Corporations, Therapeutics	Drug Delivery, Drug Discovery, Therapeutics, Wellness solutions	Clinical Stage, Public Company
Alliance Scientific	Biotechnology, Scientific Supplies	Manufacturer, Product Development	Commercial Stage, Private Company
Alpha-9 Theranostics	Biotechnology, Diagnostics, Medical Technology, Therapeutics	Imaging, Oncology, Radio Pharmaceuticals, Therapeutics	Clinical Stage, Private Company, Series A Stage
Amgen British Columbia	Biotechnology, Therapeutics	Therapeutics, Wellness solutions	Public Company
Amplitude Ventures	Investors, Medical Device	Medical Device Design, Therapeutics	Private Company
AON	Financial & Insurance Services	Analytical Services, Data Management and Statistics	Public Company
Apricell Biotechnology Inc.	Biotechnology	Drug Discovery, Drug Delivery	Private Company
Arazy Group Consultants Inc.	Legal Services, Medical Device, Medical Technology, Professional Services, Strategic Consulting	Regulatory	Other
ARC Medical Devices, Inc.	Biotechnology, Medical Technology, Therapeutics	Biopolysaccharide Therapeutics	Phase 1 clinical studies, Private Company, Series A Stage
ARTMS	Biotechnology	Oncology	Private Company
Artron BioResearch Inc.	Biotechnology, Medical Device	Antibodies, Antigen, Bioprocessing, Bioproducts, Cardiovascular Disease, Genomics, Infectious Diseases, Medical Supplies, Oncology, Testing Instruments	Clinical Stage, Private Company
Aspect Biosystems	Biotechnology, Medical Technology, Therapeutics	3D Bioprinting, Cardiovascular Disease, Drug Discovery, Immune Therapy, Inflammatory Diseases, Metabolic Diseases, Neurological Diseases, Oncology, Regenerative Medicine, Therapeutics	Discovery Preclinical studies, Series A Stage
AstraZeneca Canada Inc.	Global Pharmaceutical Corporations	Cardiovascular Disease, Infectious Diseases, Metabolic Diseases, Neurological Diseases, Oncology, Vaccines	Commercial Stage, Public Company
Augurex	Biotechnology, Diagnostics	Bioanalytical Services, Bioinformatics, Wellness solutions	Private Company
Aurinia Pharma U.S., Inc.	Biotechnology, Therapeutics	Autoimmune Diseases, Therapeutics	Commercial Stage, Public Company
Aurora Biomed	Academic & Research Institutions, Biotechnology, Diagnostics, Therapeutics	Rapid Diagnostic Test Kits, Therapeutics, Wellness solutions	Commercial Stage, Private Company
Aurora BioSolutions Inc.	Biotechnology	Disease Prevention	Private Company
Australian Consulate & Trade Commission	Associations & Government	Analytical Services	Private Company
Axis	Financial & Insurance Services	Analytical Services	Private Company
Axolotl Biosciences	Biotechnology, Medical Technology, Scientific Supplies, Therapeutics	3D Bioprinting, Bioproducts, Cellular Medicine, Drug Delivery, Drug Discovery, Manufacturer, Nanomedicine, Neurological Diseases, Oncology, Reagents, Regenerative Medicine	Private Company, Start-up
Azor Biotech	Biotechnology	Drug Delivery, Drug Discovery	Private Company
Baehl Innovation	Academic & Research Institutions, Accelerators & Incubators, Associations & Government, Biotechnology, Diagnostics, Digital Health, Genomics, Global Pharmaceutical Corporations, Investors, Medical Device, Medical Technology, Professional Services, Strategic Consulting, Therapeutics	3D Bioprinting, Antibodies, Antigen, Artificial Intelligence, Autoimmune Diseases, Bioinformatics, Biologic Medicines, Bioprocessing, Bioproducts, Cardiovascular Disease, Cellular Medicine, cGMP/GLP Compliance, Contract Manufacturing, Digital Monitoring, Drug Discovery, Gene Therapy, Genomics, Health Tech, High-throughput Screening, Immune Therapy, Infectious Diseases, Inflammatory Diseases, Medical Equipment, Metabolic Diseases, Microbiome, Molecular Diagnostics, mRNA, Nanomedicine, Natural Compounds, Neurological Diseases, Neurophysiology, Nutrition, Oncology, Ophthalmology, Pediatrics, Pre-Clinical Services, Product Development, Proteomics, Quality Assurance, Regenerative Medicine, Remote Monitoring, Renal & Kidney Disease, Restorative and Repair Medicine, Teaching and Training, Telehealth, Therapeutics, Toxicology, Vaccines, VR/AR, Women's Health	Private Company
Bausch Health	Global Pharmaceutical Corporations	Bioprocessing, Bioproducts, Distributor, Drug Discovery, Manufacturer, Ophthalmology, Product Development, Wellness solutions	Private Company
BC Academic Health Science Network / Clinical Trials BC	Contract Research & Scientific Services	Analytical Services, Data Management and Statistics	
BC Tech Association	Associations & Government, Not-for-profit	Bioinformatics, Teaching and Training	
BCIT, Department of Biotechnology	Academic & Research Institutions	Teaching and Training	Other



# Funding opportunities for growth

## *Hire a student today*

Hire talent eager to utilize their skills, and help develop new talent for future recruitment needs

Email Colleen at [askme@biotalent.ca](mailto:askme@biotalent.ca)  
or visit [biotalent.ca/Co-opFunds](https://biotalent.ca/Co-opFunds)



Igniting the bio-economy's brainpower

Funded in part by the Government of Canada's Student Work Placement Program.

Canada 

© 2022 BioTalent Canada is a registered trademark of BioTalent Canada. BioTalent is a trademark of BioTalent Canada.

Photo taken at BioTalent Canada wage subsidy employer Precision Biomonitoring

## LIFE SCIENCES COMPANIES AT A GLANCE

PLEASE REFER TO <a href="http://LIFESCIENCESBC.CA">LIFESCIENCESBC.CA</a> FOR FURTHER INFORMATION ON THESE COMPANIES			
Company Name	Sector	Area of Expertise	Company Stage
Beazley Group	Financial & Insurance Services	Analytical Services, Data Management and Statistics	Other
BeiGene Canada	Biotechnology, Global Pharmaceutical Corporations	Immune Therapy, Inflammatory Diseases, Oncology	Clinical Stage, Commercial Stage, Discovery Preclinical studies, Phase 1 clinical studies, Phase 2 clinical studies, Phase 3 clinical studies, Phase 4 clinical studies, Public Company
Berkley Canada	Financial & Insurance Services	Analytical Services, Data Management and Statistics	Private Company
Bioasis Technologies Inc.	Biotechnology	Drug Delivery, Neurological Diseases, Oncology	Clinical Stage, Public Company
BioBoost Synbio Consulting Inc	Biotechnology, Contract Research & Scientific Services, Genomics	Bioprocessing, Bioproducts, Contract Manufacturing, Manufacturer, Product Development	Private Company
biofilm MEDIA	Media & Communications, Professional Services	Imaging	Private Company
bioLytical Laboratories Inc.	Medical Device	Rapid Diagnostic Test Kits	Other
BioTalent Canada	Associations & Government, Biotechnology, Not-for-profit, Professional Services	Teaching and Training	Private Company
BIOTECCanada	Academic & Research Institutions, Accelerators & Incubators, Associations & Government, Biotechnology, Contract Research & Scientific Services, Diagnostics, Digital Health, Global Pharmaceutical Corporations, Investors, Legal Services, Medical Technology, Professional Services, Therapeutics	Teaching and Training	Private Company
Blake, Cassels & Graydon LLP	Legal Services	Regulatory	
Boehringer Ingelheim	Biotechnology, Global Pharmaceutical Corporations, Therapeutics	Cardiovascular Disease, Metabolic Diseases, Oncology, Therapeutics	Clinical Stage, Commercial Stage, Public Company
Bold Therapeutics Inc.	Biotechnology, Therapeutics	Infectious Diseases, Oncology, Therapeutics	Clinical Stage, Phase 1 clinical studies, Phase 2 clinical studies, Series B Stage
Boreal Genomics Inc.	Biotechnology, Diagnostics, Genomics	Medical Device Design, Oncology	Commercial Stage
Brevisretero Corporation	Biotechnology, Contract Research & Scientific Services, IT & Software Services, Lab Services, Professional Services, Strategic Consulting, Therapeutics	Analytical Services, Antibodies, Artificial Intelligence, Bioprocessing, cGMP/GLP Compliance, Contract Manufacturing, Drug Delivery, Drug Discovery, Gene Therapy, mRNA, Oncology, Pre-Clinical Services, Product Development, Therapeutics, Toxicology, Vaccines	Start-up
BRI Biopharmaceutical Research Inc.	Contract Research & Scientific Services	Bioanalytical Services	Public Company
Brigene Biosciences Inc.	Biotechnology, Contract Research & Scientific Services, Genomics, Professional Services, Therapeutics	Drug Delivery, Drug Discovery	Private Company
Brighton Group Health Industry Solutions	Digital Health, Investors	Health-care IT software, Medical Software, Telehealth	
British Columbia Centre for Excellence in HIV/AIDS	Academic & Research Institutions, Genomics, Lab Services, Not-for-profit, Therapeutics	Analytical Services, Bioanalytical Services, Bioinformatics, Cardiovascular Disease, Diabetes, Disease Prevention, Drug Delivery, Drug Discovery, Genomics, Infectious Diseases, Mental & Behavioural Health, Public Health, Therapeutics, Vaccines, Women's Health	
British Columbia Securities Commission	Professional Services	Regulatory	Other
Cagley Johnson Consulting Inc.	Biotechnology, Contract Research & Scientific Services, Professional Services, Strategic Consulting	Contract Manufacturing, Data Management and Statistics, Neurological Diseases, Oncology, Regulatory, Study Monitoring and Reporting, Therapeutics, Toxicology	
Canadian Alliance for Skills & Training in Life Sciences (CASTL)	Academic & Research Institutions, Biotechnology, Not-for-profit	Teaching and Training	
Canary Medical Inc	Biotechnology, Diagnostics, Digital Health, Medical Device, Medical Technology	Bioanalytical Services, Data Management and Statistics, Digital Monitoring, Medical Device Design, Medical Software, Telehealth, Testing Instruments, Wellness solutions	Commercial Stage, Private Company
Canexia Health	Genomics	Artificial Intelligence, Bioinformatics, Genomics, Oncology, Therapeutics	
Celgene Inc.	Biotechnology, Global Pharmaceutical Corporations, Therapeutics	Bioanalytical Services, Bioinformatics, Bioprocessing, Bioproducts, Disease Prevention, Distributor, Drug Delivery, Drug Discovery, Pathology Services, Therapeutics, Wellness solutions	Commercial Stage, Private Company
Centre for Health Evaluation and Outcome Sciences (CHEOS)	Academic & Research Institutions	Autoimmune Diseases, Bioinformatics, Cardiovascular Disease, Data Management and Statistics, Digital Monitoring, Genomics, Health-care IT software, Infectious Diseases, Inflammatory Diseases, Mental & Behavioral Health, Metabolic Diseases, Public Health, Quality Assurance, Regulatory, Remote Monitoring, Study Monitoring and Reporting, Teaching and Training, Telehealth, Women's Health	Phase 1 clinical studies, Phase 2 clinical studies, Phase 3 clinical studies, Phase 4 clinical studies
CEQUAL Inc.	Biotechnology, Contract Research & Scientific Services, Therapeutics	Bioanalytical Services, Bioprocessing, Genomics, Therapeutics, Wellness solutions	Clinical Stage, Private Company
Chernoff Thompson Architects	Academic & Research Institutions, Facilities & Real Estate, Professional Services	Regulatory	
Chinook Contract Research Inc.	Contract Research & Scientific Services	Medical Device Design	Private Company
Chinook Therapeutics Inc.	Biotechnology, Therapeutics	Therapeutics	Clinical Stage, Public Company
Christensen O'Connor Johnson Kindness PLLC	Legal Services, Strategic Consulting	Regulatory	
Clairvoyant Therapeutics Inc.	Therapeutics	Drug Discovery, Infectious Diseases, Inflammatory Diseases, Manufacturer, Therapeutics	Phase 2 clinical studies, Private Company, Series A Stage, Start-up
Clarix Healthcare	Digital Health, Medical Device, Medical Technology	Remote Monitoring, Telehealth	
Coast Communications and Public Affairs	Media & Communications, Strategic Consulting	Public Health	Commercial Stage, Private Company
Corcym Canada Corp.	Medical Device	Cardiovascular Disease, cGMP/GLP Compliance, Contract Manufacturing, Manufacturer, Medical Device Design	Commercial Stage, Private Company
Cureimmune Therapeutics Inc.	Biotechnology, Therapeutics	Antibodies, Autoimmune Diseases, Immune Therapy, Oncology	Discovery Preclinical studies



PLEASE REFER TO <a href="https://lifesciencesbc.ca">LIFESCIENCESBC.CA</a> FOR FURTHER INFORMATION ON THESE COMPANIES			
Company Name	Sector	Area of Expertise	Company Stage
Cytiva	Biotechnology, Contract Research & Scientific Services, Scientific Supplies	Antibodies, Antigen, Bioprocessing, Bioproducts, Contract Manufacturing, Drug Discovery, Gene Therapy, High-throughput Screening, Imaging, Immune Therapy, Manufacturer, Molecular Diagnostics, Product Development, Reagents, Teaching and Training, Therapeutics, Vaccines	Other
Deloitte LLP	Financial & Insurance Services	Regulatory	Private Company
Delta-Fly Pharma Inc.	Therapeutics	Disease Prevention, Drug Delivery, Drug Discovery, Oncology, Therapeutics	Phase 3 clinical studies, Public Company
Derm-Biome Pharmaceuticals Inc	Biotechnology, Therapeutics	Autoimmune Diseases, Inflammatory Diseases, Neurological Diseases	Discovery Preclinical studies, Private Company, Seed Stage
DigbyGlobal	Legal Services	Regulatory	Private Company
Digital Supercluster	Associations & Government, Digital Health, Funding Agencies, Not-for-profit	Artificial Intelligence, Bioinformatics, Data Management and Statistics, Digital Monitoring, Health-care IT software, High-throughput Screening, Imaging, Medical Software, Molecular Diagnostics	Private Company
Discovery DNA Inc.	Genomics	Genomics	Private Company
Domain Therapeutics NA Inc.	Biotechnology, Therapeutics	Antibodies, Autoimmune Diseases, Cardiovascular Disease, Drug Discovery, Immune Therapy, Inflammatory Diseases, Metabolic Diseases, Neurological Diseases, Oncology, Therapeutics	Discovery Preclinical studies, Private Company
DP Labs and Biotechnology Inc.	Medical Device	Medical Device Design, Product Development	
Dr. Ma's Laboratories	Biotechnology, Therapeutics	Manufacturer, Therapeutics	Commercial Stage, Private Company
Electromate Inc.	Medical Device, Professional Services	3D Bioprinting, Distributor, Remote Monitoring	Other
Embassy of the Republic of Lithuania to Canada	Associations & Government	Regulatory	Other
EMD Serono	Global Pharmaceutical Corporations	Bioproducts	Private Company
EMMES Canada	Contract Research & Scientific Services	Data Management and Statistics, Infectious Diseases, Inflammatory Diseases, Ophthalmology, Public Health, Regulatory, Remote Monitoring, Study Monitoring and Reporting, Vaccines	Other
EMPOWER Psychedelics	Academic & Research Institutions, Biotechnology, Therapeutics	Data Management and Statistics, Distributor, Drug Delivery, Mental & Behavioural Health, Neurophysiology, Pre-Clinical Services, Public Health, Regulatory	Discovery Preclinical studies, Private Company, Seed Stage
entrepreneurship@UBC	Academic & Research Institutions, Accelerators & Incubators, Not-for-profit	Teaching and Training	Pre-Seed stage, Seed Stage, Series A Stage, Start-up
eSenso Biotech Inc.	Academic & Research Institutions, Biotechnology, Contract Research & Scientific Services, Diagnostics, Digital Health, Lab Services, Medical Device, Medical Technology, Scientific Supplies, Therapeutics	Analytical Services, Antibodies, Antigen, Autoimmune Diseases, Bioanalytical Services, Bioproducts, Cardiovascular Disease, Contract Manufacturing, Digital Monitoring, Environmental, Infectious Diseases, Manufacturer, Medical Device Design, Medical Equipment, Medical Supplies, Molecular Diagnostics, Product Development, Public Health, Rapid Diagnostic Test Kits, Reagents, Regulatory, Remote Monitoring, Teaching and Training, Testing Instruments	
ESSA Pharma Inc.	Therapeutics	Bioinformatics, Bioprocessing, Bioproducts, Cellular Medicine, Distributor, Drug Delivery, Drug Discovery, Oncology, Therapeutics, Wellness solutions	
Eupraxia Pharmaceuticals Inc.	Therapeutics	Drug Delivery, Drug Discovery	Clinical Stage, Discovery Preclinical studies, Phase 2 clinical studies, Public Company
Evonik Health Care	Biotechnology, Contract Research & Scientific Services, Scientific Supplies	cGMP/GLP Compliance, Contract Manufacturing, Drug Delivery, Gene Therapy, Immune Therapy, Infectious Diseases, mRNA, Nanomedicine, Oncology, Pre-Clinical Services, Therapeutics, Vaccines	Public Company
EY	Financial & Insurance Services, Investors, Strategic Consulting	Analytical Services, Data Management and Statistics	Private Company
Farabloc Development Corp.	Biotechnology, Medical Device, Medical Technology, Scientific Supplies	Distributor, Manufacturer, Medical Supplies, Product Development, Public Health, Therapeutics, Wellness solutions, Women's Health	Commercial Stage, Private Company
Farris LLP	Legal Services	Regulatory	Private Company
Fasken LLP	Legal Services	Regulatory	
Fusion Genomics Corporation	Diagnostics, Genomics	Bioinformatics, Genomics, Infectious Diseases, Molecular Diagnostics, Reagents	Series A Stage
Gairdner Foundation	Associations & Government, Not-for-profit	Public Health	
Gandeeva Therapeutics	Biotechnology	Therapeutics	Private Company, Start-up
Gemina Laboratories	Biotechnology, Diagnostics, Medical Device, Medical Technology	Infectious Diseases, Molecular Diagnostics, Rapid Diagnostic Test Kits, Wellness solutions	Public Company, Start-up
Gene Bio Medical	Biotechnology, Medical Technology	Medical Device Design	Private Company
Genevant Sciences, Corp.	Biotechnology, Therapeutics	Drug Delivery, Drug Discovery, mRNA	
Genome British Columbia	Academic & Research Institutions, Accelerators & Incubators, Associations & Government, Biotechnology, Funding Agencies, Genomics, Not-for-profit	Genomics	
Gilead Sciences Inc.	Biotechnology, Global Pharmaceutical Corporations, Therapeutics	Cardiovascular Disease, Cellular Medicine, Infectious Diseases, Inflammatory Diseases, Oncology	Commercial Stage
Glaxosmithkline Inc. / GSK	Global Pharmaceutical Corporations, Therapeutics	Bioinformatics, Bioprocessing, Bioproducts, Cardiovascular Disease, Disease Prevention, Distributor, Drug Delivery, Drug Discovery, Infectious Diseases, Manufacturer, Oncology, Product Development, Therapeutics, Vaccines, Wellness solutions, Women's Health	Public Company
Gowling WLG (Canada) LLP	Legal Services	Regulatory	

## LIFE SCIENCES COMPANIES AT A GLANCE

PLEASE REFER TO <a href="http://LIFESCIENCESBC.CA">LIFESCIENCESBC.CA</a> FOR FURTHER INFORMATION ON THESE COMPANIES			
Company Name	Sector	Area of Expertise	Company Stage
Grantek	IT & Software Services, Professional Services, Strategic Consulting	Analytical Services, Bioprocessing, cGMP/GLP Compliance, Contract Manufacturing, Data Management and Statistics, Health-care IT software, Medical Software, Product Development, Study Monitoring and Reporting, Testing Instruments	Private Company
Groupe PARIMA Inc.	Contract Research & Scientific Services, Lab Services, Medical Device, Scientific Supplies	Analytical Services, Contract Manufacturing, Manufacturer, Product Development	Clinical Stage, Commercial Stage, Discovery Preclinical studies, Phase 1 clinical studies, Phase 2 clinical studies, Phase 3 clinical studies, Phase 4 clinical studies, Private Company
GuideStar Medical Devices	Medical Device	Medical Device Design	Private Company
Hamilton Company	Therapeutics	Medical Equipment, Medical Supplies	
HDR	Facilities & Real Estate, Lab Services, Professional Services, Strategic Consulting	cGMP/GLP Compliance, Oncology, Public Health, Teaching and Training	Private Company
Health and Technology District	Academic & Research Institutions, Biotechnology, Diagnostics, Digital Health, Medical Device, Medical Technology, Therapeutics	Antibodies, Antigen, Artificial Intelligence, Bioinformatics, Bioprocessing, Bioproducts, Cardiovascular Disease, Cellular Medicine, Data Management and Statistics, Digital Monitoring, Disease Prevention, Drug Delivery, Drug Discovery, Gene Therapy, Genomics, Health-care IT software, High-throughput Screening, Imaging, Immune Therapy, Infectious Diseases, Inflammatory Diseases, Medical Equipment, Medical Software, Medical Supplies, Molecular Diagnostics, Product Development, Testing Instruments, Therapeutics, Wellness solutions, Women's Health	
HealthQB	Digital Health	Medical Device Design, Neurophysiology	
Hoffmann-La Roche Ltd.	Biotechnology, Global Pharmaceutical Corporations, Medical Technology, Therapeutics	Bioinformatics, Bioprocessing, Bioproducts, Distributor, Manufacturer, Oncology, Ophthalmology, Rapid Diagnostic Test Kits, Therapeutics	Commercial Stage, Public Company
Horizon Therapeutics Canada	Global Pharmaceutical Corporations, Therapeutics	Bioinformatics, Bioprocessing, Bioproducts, Drug Discovery, Metabolic Diseases, Product Development, Therapeutics	Public Company
HTuO Biosciences Inc.	Biotechnology, Contract Research & Scientific Services	Bioinformatics, Drug Discovery, Therapeutics	Discovery Preclinical studies, Pre-Seed stage, Private Company, Start-up
ICORD	Academic & Research Institutions, Biotechnology, Therapeutics	Bioanalytical Services, Bioinformatics, Medical Device Design, Medical Equipment, Medical Software, Medical Supplies, Molecular Diagnostics, Therapeutics, Wellness solutions	Clinical Stage, Private Company
IKOMED Technologies Inc.	Medical Device, Medical Technology	Artificial Intelligence, cGMP/GLP Compliance, Data Management and Statistics, Imaging, Manufacturer, Medical Device Design	Commercial Stage, Discovery Preclinical studies, Start-up
Incisive Genetics Inc.	Biotechnology, Genomics, Global Pharmaceutical Corporations, Therapeutics	Cellular Medicine, Disease Prevention, Drug Delivery, Drug Discovery, Gene Therapy, Genomics, Nanomedicine, Product Development, Therapeutics	Private Company, Seed Stage
InMed Pharmaceuticals Inc.	Biotechnology, Therapeutics	Bioinformatics, Bioprocessing, Bioproducts, Drug Delivery, Drug Discovery, Ophthalmology, Product Development, Therapeutics, Wellness solutions	Phase 2 clinical studies
InnoTech Medical Industries Corp.	Biotechnology, Diagnostics, Digital Health, Medical Device, Medical Technology	Bioanalytical Services, Bioinformatics, Imaging, Medical Device Design, Medical Equipment, Medical Software, Medical Supplies, Product Development	Clinical Stage, Commercial Stage, Private Company
Innovatek Medical Inc.	Biotechnology, Diagnostics, Medical Device, Medical Technology	Bioanalytical Services, Bioinformatics, Bioprocessing, Bioproducts, Distributor, Manufacturer, Medical Equipment, Medical Supplies, Molecular Diagnostics, Product Development, Rapid Diagnostic Test Kits, Testing Instruments	Commercial Stage, Private Company
Innovative Medicines Canada	Associations & Government, Biotechnology, Global Pharmaceutical Corporations, Therapeutics	Bioanalytical Services, Bioinformatics, Bioprocessing, Bioproducts, Distributor, Drug Delivery, Drug Discovery, Manufacturer, Wellness solutions	Commercial Stage, Private Company
Innovative Targeting Solutions Inc.	Biotechnology, Therapeutics	Antibodies, Cellular Medicine, Drug Discovery, High-throughput Screening, Immune Therapy	Discovery Preclinical studies
Institute of Health Economics (IHE)	Biotechnology, Financial & Insurance Services, Investors, Medical Device, Not-for-profit	Analytical Services, Bioanalytical Services, Bioinformatics, Data Management and Statistics, Medical Software	Private Company
Integrated Nanotherapeutics Inc.	Diagnostics, Therapeutics	Therapeutics	Private Company
IonsGate Preclinical Services Inc.	Biotechnology, Contract Research & Scientific Services, Therapeutics	Bioanalytical Services, Bioinformatics, Bioprocessing, Bioproducts, Cardiovascular Disease, Cellular Medicine, Drug Discovery, Pre-Clinical Services	Commercial Stage, Private Company
iProgen Biotech Inc.	Biotechnology	Antibodies, Drug Delivery, Drug Discovery, Immune Therapy, Neurological Diseases, Oncology, Regenerative Medicine	
IRICoR	Not-for-profit, Therapeutics	Therapeutics	Private Company
Izotropic Corporation	Diagnostics, Digital Health, Medical Device	Imaging, Medical Device Design, Medical Equipment, Oncology, Women's Health	Discovery Preclinical studies, Public Company
Janssen Inc.	Biotechnology, Global Pharmaceutical Corporations, Therapeutics	Bioanalytical Services, Bioinformatics, Bioprocessing, Bioproducts, Cardiovascular Disease, Cellular Medicine, Drug Delivery, Drug Discovery, Gene Therapy, Genomics, Immune Therapy, Infectious Diseases, Inflammatory Diseases, Manufacturer, Molecular Diagnostics, mRNA, Nanomedicine, Neurological Diseases, Neurophysiology, Oncology, Therapeutics, Vaccines	Commercial Stage, Private Company
Jerzy's Corner	Facilities & Real Estate	Manufacturer	Private Company
Kapoose Creek Wellness	Biotechnology, Therapeutics	Therapeutics	Start-up
Kardium Inc.	Biotechnology, Medical Device, Medical Technology	Cardiovascular Disease, Medical Supplies	
Kintara Therapeutics	Biotechnology, Therapeutics	Bioanalytical Services, Bioinformatics, Bioprocessing, Bioproducts, Cellular Medicine, Oncology, Therapeutics	Clinical Stage, Public Company
Kirke Management Consulting	Professional Services	Analytical Services	Private Company
KPMG LLP	Financial & Insurance Services	Analytical Services	Private Company

PLEASE REFER TO <a href="http://LIFESCIENCESBC.CA">LIFESCIENCESBC.CA</a> FOR FURTHER INFORMATION ON THESE COMPANIES			
Company Name	Sector	Area of Expertise	Company Stage
Lg BioScience Inc.	Biotechnology	Analytical Services, Bioanalytical Services, Bioinformatics, Bioprocessing, Bioproducts, Drug Discovery, Product Development	Private Company
LAST Innovations Ltd.	Therapeutics	Artificial Intelligence, Bioproducts, Drug Discovery, Genomics, Immune Therapy, Oncology, Product Development, Therapeutics	Discovery Preclinical studies, Private Company, Seed Stage
Libang Capital (Canada) Limited	Funding Agencies, Investors	Analytical Services	Private Company
Libang Surgical Technologies	Biotechnology, Medical Device, Medical Technology, Scientific Supplies	Manufacturer, Medical Device Design, Medical Equipment, Medical Software	Private Company
LifeLabs	Diagnostics, Digital Health, Lab Services, Professional Services	Digital Monitoring, Genomics, Health-care IT software, Molecular Diagnostics, Pathology Services, Public Health, Wellness solutions, Women's Health	Other
Lumira Ventures	Funding Agencies, Investors	Regulatory	Private Company
Manzanita Pharmaceuticals, Inc.	Biotechnology, Medical Technology	Molecular Diagnostics, Neurophysiology	Private Company
McCarthy Tetrault LLP	Financial & Insurance Services, Legal Services, Strategic Consulting	Regulatory	
Me Therapeutics Inc.	Biotechnology, Global Pharmaceutical Corporations, Therapeutics	Bioanalytical Services, Bioinformatics, Bioprocessing, Bioproducts, Cellular Medicine, Immune Therapy, Infectious Diseases, Inflammatory Diseases, Manufacturer, Oncology, Product Development, Therapeutics, Wellness solutions	Commercial Stage, Private Company
Merck Canada Inc.	Global Pharmaceutical Corporations	Bioinformatics, Bioprocessing, Bioproducts, Drug Delivery, Drug Discovery, Infectious Diseases, Inflammatory Diseases, Manufacturer, Oncology, Product Development, Therapeutics, Vaccines, Wellness solutions	Commercial Stage, Private Company
Mesentech	Biotechnology, Therapeutics	Bioanalytical Services, Bioinformatics, Bioprocessing, Bioproducts, Cellular Medicine, Disease Prevention, Distributor, Drug Delivery, Drug Discovery, Genomics, Inflammatory Diseases, Manufacturer, Product Development, Regenerative Medicine, Therapeutics, Wellness solutions	Commercial Stage, Private Company
Mesintel Therapeutics Inc.	Biotechnology, Therapeutics	Therapeutics	Private Company
Metamor Health	Professional Services	Bioanalytical Services	
Metaphase Health Research Consulting, Inc.	Professional Services	Immune Therapy, Metabolic Diseases, Neurological Diseases, Oncology	
Michael Smith Health Research BC	Academic & Research Institutions, Funding Agencies, Not-for-profit	Teaching and Training	
Microbiome Insights Inc.	Contract Research & Scientific Services	Artificial Intelligence, Autoimmune Diseases, Bioinformatics, Drug Discovery, Environmental, Genomics, Infectious Diseases, Inflammatory Diseases, Mental & Behavioural Health, Metabolic Diseases, Microbiome, Neurological Diseases, Oncology, Pre-Clinical Services, Therapeutics, Women's Health	Other
Microbion Pharma Corp.	Therapeutics	Infectious Diseases, Therapeutics	Discovery Preclinical studies, Phase 2 clinical studies, Series A Stage
Ministry of Jobs, Economic Recovery and Innovation	Associations & Government	Teaching and Training	Other
Molecular Forecaster Inc.	Biotechnology, Contract Research & Scientific Services	Artificial Intelligence, Bioinformatics, Drug Discovery, Reagents, Therapeutics	Commercial Stage, Private Company, Start-up
Molecular You	Biotechnology, Digital Health, Global Pharmaceutical Corporations	Data Management and Statistics, Digital Monitoring, Drug Discovery, Health Tech, Wellness solutions	Commercial Stage, Private Company
MYND Life Sciences	Contract Research & Scientific Services	Drug Delivery, Drug Discovery	Private Company
NanoVation Therapeutics	Biotechnology, Genomics, Therapeutics	Therapeutics	Private Company
National Research Council Canada	Associations & Government, Funding Agencies, Investors	Analytical Services	
NervGen Pharma Corp.	Biotechnology, Therapeutics	Drug Discovery, Neurological Diseases, Neurophysiology, Regenerative Medicine, Therapeutics	Phase 1 clinical studies, Public Company
New Beta Innovation Canada Limited	Biotechnology, Global Pharmaceutical Corporations, Therapeutics	cGMP/GLP Compliance, Drug Discovery, Manufacturer, Neurological Diseases, Oncology, Product Development, Therapeutics, Wellness solutions	Phase 1 clinical studies, Private Company
Nimbus Synergies	Digital Health, Funding Agencies, Investors, Medical Technology	Teaching and Training	Pre-Seed stage, Private Company, Seed Stage, Series A Stage
Northview LifeSciences	Diagnostics, Investors, Medical Device, Strategic Consulting, Therapeutics	Medical Device Design, Therapeutics	Private Company
Norton Rose Fulbright Canada LLP	Legal Services	Regulatory	
Notch Therapeutics, Inc.	Biotechnology, Medical Technology, Therapeutics	Drug Discovery, Immune Therapy, Oncology, Therapeutics	Series A Stage
Novacom Building Partners	Facilities & Real Estate, Lab Services, Professional Services, Strategic Consulting		Commercial Stage, Private Company
Novartis Pharmaceuticals Canada Inc.	Biotechnology, Global Pharmaceutical Corporations, Therapeutics	Bioanalytical Services, Bioinformatics, Bioprocessing, Bioproducts, Cardiovascular Disease, Cellular Medicine, Distributor, Drug Delivery, Drug Discovery, Infectious Diseases, Inflammatory Diseases, Manufacturer, Neurological Diseases, Neurophysiology, Oncology, Product Development, Toxicology, Vaccines, Wellness solutions	Commercial Stage, Public Company
Novateur Ventures Inc.	Contract Research & Scientific Services, Investors, Professional Services, Strategic Consulting	Antibodies, Autoimmune Diseases, Cardiovascular Disease, cGMP/GLP Compliance, Contract Manufacturing, Drug Delivery, Drug Discovery, Gene Therapy, Immune Therapy, Infectious Diseases, Inflammatory Diseases, Mental & Behavioral Health, Metabolic Diseases, Neurological Diseases, Oncology, Ophthalmology, Pre-Clinical Services, Product Development, Quality Assurance, Radio Pharmaceuticals, Rapid Diagnostic Test Kits, Regulatory, Therapeutics, Toxicology, Women's Health	
Novo Nordisk Canada Inc.	Biotechnology, Global Pharmaceutical Corporations, Therapeutics	Bioinformatics, Bioprocessing, Bioproducts, Cardiovascular Disease, Cellular Medicine, Disease Prevention, Distributor, Drug Delivery, Drug Discovery, Infectious Diseases, Inflammatory Diseases, Manufacturer, Metabolic Diseases, Oncology, Pathology Services, Pediatrics, Product Development, Therapeutics, Women's Health	Commercial Stage, Public Company
Numinus Wellness Inc.	Contract Research & Scientific Services, Genomics, Lab Services, Therapeutics	Analytical Services, Mental & Behavioral Health, Psychedelics, Therapeutics, Wellness solutions	Public Company



## LIFE SCIENCES COMPANIES AT A GLANCE

PLEASE REFER TO <a href="https://lifesciencesbc.ca">LIFESCIENCESBC.CA</a> FOR FURTHER INFORMATION ON THESE COMPANIES			
Company Name	Sector	Area of Expertise	Company Stage
NZ Technologies Inc.	Digital Health, Medical Device, Medical Technology	Artificial Intelligence, Manufacturer, Medical Device Design, Medical Equipment, Product Development	
Oak Bay Biosciences	Biotechnology, Therapeutics	Bioanalytical Services, Bioinformatics, Bioprocessing, Bioproducts, Drug Delivery, Drug Discovery, Manufacturer, Ophthalmology, Product Development, Therapeutics, Wellness solutions	Private Company, Start-up
Omega Laboratories inc	Diagnostics, IT & Software Services, Lab Services, Medical Device, Medical Technology	Antibodies, Antigen, High-throughput Screening, Medical Software, Molecular Diagnostics, Pathology Services, Rapid Diagnostic Test Kits, Toxicology	Private Company
Ondine Biomedical Inc.	Biotechnology, Therapeutics	Bioanalytical Services, Bioinformatics, Distributor, Infectious Diseases, Medical Device Design, Medical Equipment, Medical Software, Product Development, Therapeutics, Vaccines	Commercial Stage, Public Company
Onestep Laboratories Inc.	Biotechnology, Diagnostics, Medical Technology, Scientific Supplies, Therapeutics	Bioanalytical Services, Bioinformatics, Bioprocessing, Bioproducts, Distributor, Drug Delivery, Drug Discovery, Manufacturer, Medical Supplies, Reagents, Therapeutics, Wellness solutions	Commercial Stage, Private Company
ORX Surgical	Biotechnology, Medical Device	Medical Device Design	Private Company
Osler, Hoskin & Harcourt LLP	Legal Services	Regulatory	Private Company
Oyen Wiggs Green & Mutala LLP	Legal Services	Regulatory	Private Company
PantRidgeDTeLL Health Technologies CORP.	Digital Health	Analytical Services, Cardiovascular Disease, Data Management and Statistics, Diabetes, Disease Prevention, Inflammatory Diseases, Medical Software, Renal & Kidney Disease, Telehealth	Discovery Preclinical studies, Private Company, Seed Stage
Paragon Ventures Inc	Professional Services, Strategic Consulting	Analytical Services, Data Management and Statistics	Private Company
Pender & Howe Executive Search	Professional Services	Artificial Intelligence, Cannabinoids, Cellular Medicine, Contract Manufacturing, Dentistry, Drug Discovery, Gene Therapy, Genomics, Health-care IT software, Health Tech, Medical Device Design, Medical Software, Metabolic Diseases, Molecular Diagnostics, mRNA, Product Development, Psychedelics, Public Health, Quality Assurance, Radio Pharmaceuticals, Rapid Diagnostic Test Kits, Regulatory, Therapeutics, VR/AR	Private Company
Pfizer Canada Inc.	Biotechnology, Global Pharmaceutical Corporations, Therapeutics	Bioinformatics, Bioprocessing, Bioproducts, Disease Prevention, Distributor, Drug Delivery, Drug Discovery, Infectious Diseases, Manufacturer, mRNA, Nanomedicine, Oncology, Therapeutics	Commercial Stage, Public Company
Pharma Inventor Inc.	Contract Research & Scientific Services	Analytical Services, Bioanalytical Services, Bioproducts, Drug Discovery, Manufacturer, Molecular Diagnostics, Pre-Clinical Services, Product Development, Radio Pharmaceuticals, Therapeutics	Discovery Preclinical studies
PharmaBioSource	Professional Services, Strategic Consulting	Analytical Services, Data Management and Statistics	Private Company
PharmaDirections, Inc.	Biotechnology, Global Pharmaceutical Corporations, Professional Services, Strategic Consulting, Therapeutics	Bioanalytical Services, Product Development, Teaching and Training, Therapeutics, Wellness solutions	Private Company
PHEMI Systems Corporation	Digital Health, IT & Software Services	Analytical Services, Artificial Intelligence, Data Management and Statistics, Health-care IT software, Medical Software	Series B Stage
Phyton Biotech LLC	Biotechnology, Contract Research & Scientific Services	cGMP/GLP Compliance, Product Development	Private Company
Platform LifeSciences	Biotechnology, Contract Research & Scientific Services, Professional Services	Data Management and Statistics, Drug Discovery, Infectious Diseases, Public Health	Phase 3 clinical studies, Private Company
Porte Communities	Facilities & Real Estate	Manufacturer	Commercial Stage, Private Company
Pramana Pharmaceuticals Inc.	Biotechnology, Therapeutics	Diabetes, Disease Prevention, Drug Discovery, Inflammatory Diseases, Metabolic Diseases, Microbiome, Therapeutics	Discovery Preclinical studies, Phase 1 clinical studies, Series A Stage
Precision NanoSystems Inc.	Academic & Research Institutions, Associations & Government, Contract Research & Scientific Services, Genomics, Global Pharmaceutical Corporations, Scientific Supplies, Therapeutics	Drug Delivery, Therapeutics	
Primary Peptides Inc.	Biotechnology, Therapeutics	Cardiovascular Disease, Drug Discovery, Neurological Diseases, Oncology, Therapeutics	Clinical Stage, Discovery Preclinical studies, Phase 1 clinical studies, Private Company, Series A Stage
Prime Site Research Solutions Inc.	Contract Research & Scientific Services, Professional Services, Strategic Consulting	Autoimmune Diseases, Bioanalytical Services, Cardiovascular Disease, Data Management and Statistics, Drug Discovery, Gene Therapy, Immune Therapy, Infectious Diseases, Inflammatory Diseases, Metabolic Diseases, Neurological Diseases, Oncology, Ophthalmology, Product Development, Public Health, Quality Assurance, Regulatory, Remote Monitoring, Study Monitoring and Reporting, Teaching and Training, Therapeutics, Vaccines	Private Company, Start-up
Providence Research	Academic & Research Institutions, Biotechnology, Therapeutics	3D Bioprinting, Antibodies, Autoimmune Diseases, Bioinformatics, Cardiovascular Disease, Disease Prevention, Genomics, Imaging, Infectious Diseases, Inflammatory Diseases, Mental & Behavioral Health, Metabolic Diseases, Ophthalmology, Pathology Services, Teaching and Training, Therapeutics, VR/AR, Wellness solutions, Women's Health	Private Company
PwC LLP	Professional Services	Regulatory	Other
Q&C Services	Biotechnology, Global Pharmaceutical Corporations, IT & Software Services, Medical Device, Professional Services, Strategic Consulting, Therapeutics	cGMP/GLP Compliance, Data Management and Statistics, Distributor, Health-care IT software, Manufacturer, Medical Software, Quality Assurance, Radio Pharmaceuticals, Rapid Diagnostic Test Kits, Regulatory, Teaching and Training, Therapeutics, Vaccines	Private Company, Other
Qu Biologics Inc.	Biotechnology, Therapeutics	Drug Discovery, Immune Therapy, Inflammatory Diseases, Oncology, Regenerative Medicine, Therapeutics, Vaccines	Clinical Stage, Phase 2 clinical studies, Series B Stage
Quark Venture LP	Biotechnology, Digital Health, Investors, Medical Device, Medical Technology, Therapeutics	Antibodies, Artificial Intelligence, Autoimmune Diseases, Cardiovascular Disease, Digital Monitoring, Drug Delivery, Drug Discovery, Gene Therapy, Genomics, Health-care IT software, Immune Therapy, Infectious Diseases, Inflammatory Diseases, Medical Device Design, Metabolic Diseases, Microbiome, mRNA, Nanomedicine, Neurological Diseases, Oncology, Radio Pharmaceuticals, Regenerative Medicine, Remote Monitoring, Therapeutics, Vaccines, Women's Health	Series A Stage, Series B Stage, Series C Stage

PLEASE REFER TO <a href="https://lifesciencesbc.ca">LIFESCIENCESBC.CA</a> FOR FURTHER INFORMATION ON THESE COMPANIES			
Company Name	Sector	Area of Expertise	Company Stage
Reboot Communications Ltd.	Media & Communications, Professional Services	Analytical Services, Data Management and Statistics	Private Company
RepliCel Life Sciences Inc.	Biotechnology, Medical Device, Therapeutics	Cellular Medicine , Medical Equipment	Clinical Stage, Phase 1 clinical studies, Phase 2 clinical studies , Phase 3 clinical studies, Public Company
Research Universities Council of British Columbia	Academic & Research Institutions	Analytical Services	Private Company
Resilience Biosciences Inc.	Therapeutics	Therapeutics	Private Company
Response Biomedical Corp.	Medical Device	Antigen, Infectious Diseases	Other
Rostrum Medical Innovations Inc.	Medical Device	Health-care IT software , Imaging, Manufacturer, Medical Device Design, Medical Equipment, Medical Software	Clinical Stage
Sanofi Canada	Global Pharmaceutical Corporations	Antibodies, Autoimmune Diseases, Cardiovascular Disease, Infectious Diseases , Inflammatory Diseases , Neurological Diseases, Oncology, Public Health, Therapeutics, Vaccines	
SCIEX	Biotechnology, Diagnostics, Medical Technology , Scientific Supplies	Bioanalytical Services, Bioinformatics, Bioprocessing , Medical Equipment, Medical Software, Medical Supplies, Therapeutics	Public Company
ScopeSys Inc.	Biotechnology, Medical Technology , Therapeutics	Drug Delivery , High-throughput Screening , Imaging, mRNA , Nanomedicine, Reagents, Therapeutics	Commercial Stage, Private Company
Seed Intellectual Property Law Group LLP	Legal Services, Strategic Consulting	Regulatory	
Sernova Corp	Therapeutics	Disease Prevention, Therapeutics	Private Company
Shackelford Pharma Inc.	Biotechnology, Therapeutics	Disease Prevention, Drug Discovery, Neurological Diseases, Product Development, Therapeutics	Phase 2 clinical studies , Series B Stage
SignalChem Lifesciences Corp.	Biotechnology, Contract Research & Scientific Services, Medical Technology , Therapeutics	Bioproducts , Drug Discovery , Oncology, Pre-Clinical Services, Product Development, Proteomics, Therapeutics	Clinical Stage, Discovery Preclinical studies, Phase 1 clinical studies, Phase 2 clinical studies
Silicon Valley Bank	Funding Agencies, Investors	Regulatory	
Simon Fraser University - Beedie School of Business	Academic & Research Institutions	Teaching and Training	Commercial Stage
Simon Fraser University - Faculty of Science	Academic & Research Institutions, Accelerators & Incubators , Biotechnology, Contract Research & Scientific Services, Diagnostics, Digital Health , Genomics, Lab Services, Medical Device, Medical Technology , Therapeutics	Analytical Services, Antibodies, Autoimmune Diseases, Bioanalytical Services, Bioinformatics, Bioproducts , Cardiovascular Disease, Cellular Medicine , Data Management and Statistics, Diabetes, Digital Monitoring, Disease Prevention, Drug Delivery , Drug Discovery , Genomics, Health Tech, High-throughput Screening , Imaging, Immune Therapy, Infectious Diseases , Medical Device Design, Mental & Behavioural Health, Metabolic Diseases , Microbiome, Molecular Diagnostics, mRNA, Nanomedicine, Neurological Diseases, Product Development, Proteomics , Public Health, Radio Pharmaceuticals, Rapid Diagnostic Test Kits, Regenerative Medicine, Remote Monitoring, Restorative and Repair Medicine, Teaching and Training, Therapeutics, Toxicology, VR/AR, Women's Health	
Sonic Incytes Medical Corp.	Diagnostics, Medical Device, Medical Technology	Artificial Intelligence, Disease Prevention, Imaging, Infectious Diseases, Inflammatory Diseases, Medical Device Design, Medical Equipment, Metabolic Diseases	Series A Stage
Sonus Microsystems	Medical Technology	Imaging, Medical Equipment	Pre-Seed stage, Start-up
St. Paul's Foundation	Academic & Research Institutions	Cardiovascular Disease, Cellular Medicine , Disease Prevention, Gene Therapy , Imaging, Immune Therapy, Infectious Diseases, Inflammatory Diseases , Mental & Behavioral Health, Metabolic Diseases , Molecular Diagnostics, Neurological Diseases, Neurophysiology, Oncology, Public Health, Teaching and Training, Therapeutics, Toxicology, Wellness solutions, Women's Health	
StarFish Medical	Biotechnology, Contract Research & Scientific Services, Diagnostics, Digital Health , Medical Device, Medical Technology , Therapeutics	Cardiovascular Disease, Cellular Medicine, Contract Manufacturing, Drug Delivery, Gene Therapy, Genomics, Imaging, Immune Therapy, Infectious Diseases, Inflammatory Diseases, Manufacturer, Medical Device Design, Medical Equipment, Metabolic Diseases, Microbiome, Molecular Diagnostics, Nanomedicine, Neurological Diseases, Neurophysiology, Oncology, Ophthalmology, Pediatrics, Product Development, Quality Assurance, Radio Pharmaceuticals, Rapid Diagnostic Test Kits, Regenerative Medicine, Regulatory, Remote Monitoring, Telehealth, Testing Instruments, Therapeutics, Toxicology, Wellness solutions, Women's Health	Commercial Stage, Private Company
STEMCELL Technologies Canada Inc.	Biotechnology, Contract Research & Scientific Services, Scientific Supplies	Cardiovascular Disease, Cellular Medicine , Genomics, Immune Therapy, Manufacturer, Medical Equipment, Oncology, Teaching and Training, Testing Instruments	Commercial Stage, Private Company
Stratesol Consulting	Professional Services	Teaching and Training	
StressMarq Biosciences Inc.	Academic & Research Institutions, Associations & Government, Biotechnology	Antibodies, Manufacturer, Neurological Diseases, Product Development, Quality Assurance, Reagents	Private Company
Sustained Therapeutics	Academic & Research Institutions, Therapeutics	Imaging, Medical Device Design	Clinical Stage, Phase 2 clinical studies , Seed Stage, Start-up
Symvivo Corporation	Biotechnology, Genomics, Therapeutics	Bioinformatics, Bioprocessing, Cellular Medicine, Drug Delivery, Immune Therapy, Oncology, Proteomics, Therapeutics, Vaccines, Wellness solutions	Clinical Stage, Private Company
Takeda Canada Inc.	Biotechnology, Global Pharmaceutical Corporations, Therapeutics	Bioinformatics, Bioprocessing , Bioproducts, Cellular Medicine, Distributor, Drug Delivery, Drug Discovery, Neurophysiology, Oncology, Product Development	Commercial Stage, Public Company
Tel-Array Diagnostics Inc.	Biotechnology, Diagnostics, Medical Device, Medical Technology	Antibodies, Antigen, Cardiovascular Disease, Medical Device Design, Molecular Diagnostics, Oncology	Private Company, Series A Stage
The High Technology Facilities Group at CBRE Ltd.	Facilities & Real Estate, Professional Services	Manufacturer	Public Company

# LIFE SCIENCES COMPANIES AT A GLANCE

PLEASE REFER TO <a href="https://lifesciencesbc.ca">LIFESCIENCESBC.CA</a> FOR FURTHER INFORMATION ON THESE COMPANIES			
Company Name	Sector	Area of Expertise	Company Stage
Third Quarter Consulting Group	Biotechnology, Global Pharmaceutical Corporations, Medical Device, Professional Services, Strategic Consulting		Private Company
Thrive Health	Digital Health , IT & Software Services	Health-care IT software , Pre-Clinical Services, Public Health, Wellness solutions	Commercial Stage, Private Company
TRIUMF Innovations	Biotechnology, Lab Services, Scientific Supplies, Therapeutics	Bioanalytical Services, Bioinformatics, Medical Device Design, Medical Equipment, Medical Software , Medical Supplies, Regenerative Medicine, Teaching and Training, Therapeutics, Wellness solutions	
UBC Faculty of Medicine - Academy of Translational Medicine	Academic & Research Institutions, Biotechnology, Therapeutics	Cellular Medicine, Drug Delivery, Drug Discovery, Therapeutics, Wellness solutions, Women's Health	Private Company
University of British Columbia - Faculty of Medicine	Academic & Research Institutions	Antibodies, Antigen, Artificial Intelligence, Autoimmune Diseases, Bioinformatics, Cardiovascular Disease, Cellular Medicine, Data Management and Statistics, Disease Prevention, Drug Delivery, Drug Discovery, Gene Therapy, Genomics, High-throughput Screening, Imaging, Immune Therapy, Infectious Diseases, Inflammatory Diseases, Mental & Behavioural Health, Metabolic Diseases, Microbiome, Molecular Diagnostics, mRNA, Nanomedicine, Neurological Diseases, Neurophysiology, Oncology, Ophthalmology, Pediatrics, Proteomics, Public Health, Regenerative Medicine, Teaching and Training, Therapeutics, Toxicology, Vaccines, Wellness solutions, Women's Health	
University of British Columbia - Faculty of Pharmaceutical Sciences	Academic & Research Institutions, Biotechnology, Facilities & Real Estate, Therapeutics	Bioinformatics, Bioprocessing, Bioproducts, Cellular Medicine, Teaching and Training, Therapeutics, Wellness solutions	Private Company
University of British Columbia - School of Biomedical Engineering	Academic & Research Institutions	3D Bioprinting, Antibodies, Artificial Intelligence, Autoimmune Diseases, Bioinformatics, Bioproducts, Cardiovascular Disease, Cellular Medicine, Drug Delivery, Drug Discovery, Gene Therapy, Genomics, High-throughput Screening, Imaging, Immune Therapy, Inflammatory Diseases, Medical Device Design, Mental & Behavioural Health, Metabolic Diseases, Microbiome, Molecular Diagnostics, mRNA, Neurological Diseases, Oncology, Ophthalmology, Proteomics, Rapid Diagnostic Test Kits, Regenerative Medicine, Teaching and Training, Therapeutics, Vaccines, VR/AR	
Vancouver Coastal Health Research Institute (VCHRI)	Academic & Research Institutions, Biotechnology, Digital Health , Medical Technology	Artificial Intelligence, Autoimmune Diseases, Bioinformatics, Cardiovascular Disease, Data Management and Statistics, Digital Monitoring, Disease Prevention, Drug Delivery, Drug Discovery, Environmental, Gene Therapy, Genomics, Health-care IT software, High-throughput Screening, Imaging, Immune Therapy, Infectious Diseases , Inflammatory Diseases, Medical Equipment, Medical Software, Mental & Behavioral Health, Metabolic Diseases, Microbiome, Molecular Diagnostics, mRNA, Nanomedicine, Neurological Diseases, Neurophysiology, Oncology, Ophthalmology, Pathology Services, Pediatrics, Public Health, Quality Assurance, Regenerative Medicine, Regulatory, Remote Monitoring, Study Monitoring and Reporting, Teaching and Training, Telehealth, Therapeutics, Vaccines, Wellness solutions, Women's Health	
Variational AI	Biotechnology, Medical Technology , Therapeutics	Artificial Intelligence, Oncology, Therapeutics	Discovery Preclinical studies , Seed Stage
Virogin Biotech Canada Ltd.	Biotechnology, Therapeutics	Drug Delivery, Drug Discovery, Oncology, Product Development, Therapeutics	Phase 1 clinical studies, Private Company
VoxCell BioInnovation	Biotechnology, Lab Services, Medical Technology	3D Bioprinting, Bioproducts, Drug Delivery, Drug Discovery, High-throughput Screening, Medical Software, Nanomedicine, Oncology, Pre-Clinical Services, Product Development, Testing Instruments	Seed Stage, Start-up
VWR International Ltd. (Avantor)	Biotechnology, Diagnostics, Digital Health , Genomics, Lab Services, Medical Device, Medical Technology , Scientific Supplies, Therapeutics	Distributor	Commercial Stage, Private Company
Wales McLelland Construction	Facilities & Real Estate	Manufacturer	Private Company
WestPAR Consultancy Inc.	Strategic Consulting	Analytical Services , Data Management and Statistics	Commercial Stage
WEX Pharmaceuticals Inc.	Biotechnology, Therapeutics	Bioanalytical Services, Bioprocessing, Bioproducts, Distributor, Drug Delivery, Drug Discovery, Manufacturer, Neurophysiology, Therapeutics, Wellness solutions	Commercial Stage, Private Company
Willow Biosciences	Biotechnology, Global Pharmaceutical Corporations, Therapeutics	Bioprocessing, Bioproducts, Manufacturer, Product Development, Therapeutics, Wellness solutions	Commercial Stage, Public Company
World Courier , an AmerisourceBergen company	Academic & Research Institutions, Biotechnology, Diagnostics, Digital Health , Genomics, Global Pharmaceutical Corporations, Lab Services, Medical Technology , Professional Services, Therapeutics	Analytical Services, Bioanalytical Services, Data Management and Statistics, Molecular Diagnostics	Commercial Stage, Private Company
XCO Tech Inc	Digital Health , Medical Device, Medical Technology	Artificial Intelligence, Data Management and Statistics, Digital Monitoring, Disease Prevention, Health-care IT software, Health Tech, Manufacturer, Medical Device Design, Medical Equipment, Medical Software, Product Development, Remote Monitoring, Wellness solutions	Private Company, Seed Stage, Start-up
Xenon Pharmaceuticals Inc.	Biotechnology, Therapeutics	Drug Delivery, Drug Discovery, Neurological Diseases, Pediatrics, Therapeutics	Clinical Stage, Public Company
Zifo RND Solutions	IT & Software Services , Lab Services, Professional Services, Strategic Consulting	Analytical Services, Artificial Intelligence, Bioanalytical Services, Bioinformatics, Bioprocessing, Data Management and Statistics, Drug Discovery, Gene Therapy, Genomics, High-throughput Screening, Imaging, Medical Equipment, Pre-Clinical Services, Regulatory	
Zucara Therapeutics Inc.	Biotechnology, Therapeutics	Autoimmune Diseases, Drug Discovery, Metabolic Diseases, Product Development, Therapeutics	Clinical Stage, Phase 1 clinical studies, Private Company
Zymeworks Inc.	Biotechnology, Therapeutics	Antibodies, Bioprocessing , Drug Discovery , Immune Therapy, Oncology, Product Development, Therapeutics	Clinical Stage, Discovery Preclinical studies, Phase 1 clinical studies, Phase 2 clinical studies , Phase 3 clinical studies, Public Company

## LIFE SCIENCES BC MEMBERSHIP DIRECTORY

## ACADEMIC &amp; RESEARCH INSTITUTIONS

**adMare BioInnovations**

2405 Westbrook Mall, 4th Floor,  
Vancouver, BC, V6T 1Z3,  
604-827-1147 admarebio.com

**Aurora Biomed**

1001 East Pender St., Vancouver, BC, V6A  
1W2, aurorabiomed.com

**Baehl Innovation**

1055 West Georgia Street Suite 2430,  
Vancouver, V6E 3N6, baehl-innovation.com

**BCIT, Department of Biotechnology**

3700 Willingdon Ave., Burnaby, BC, V5G 3H2,  
604-432-8955 bcit.ca



BRITISH COLUMBIA  
CENTRE for EXCELLENCE  
in HIV/AIDS

**British Columbia Centre for Excellence in HIV/AIDS**

608 - 1081 Burrard Street,  
Vancouver, BC, V6Z 1Y6,  
604-806-8477 bccfe.ca

**Canadian Alliance for Skills & Training in Life Sciences (CASTL)**

302-134 Kent Street, Charlottetown, C1A 8R8,  
403-701-2815 castlcanada.ca

**Centre for Health Evaluation and Outcome Sciences (CHEOS)**

588-1081 Burrard Street,  
Vancouver, BC, V6Z 1Y6,  
604-806-9958 cheos.ubc.ca

**EMPOWER Psychedelics**

210-2695 Granville Street, Vancouver, BC,  
Canada, Vancouver, BC, V6H 3H4,  
604-897-9115 empowerresearch.org

**entrepreneurship@UBC**

2366 Main Mall, Vancouver, BC, V6T 1Z4,  
entrepreneurship.ubc.ca

**Genome British Columbia**

400 - 575 West 8th Avenue,  
Vancouver, BC, V5Z 0C4,  
604-738-8072 genomebc.ca

**ICORD**

818 West 10th Avenue,  
Vancouver, BC, V5Z 1M9,  
604-675-8800 icord.org

**Michael Smith Health Research BC**

Suite 200, 1285 West Broadway,  
Vancouver, BC, V6H 3X8,  
604-730-8322 healthresearchbc.ca

**Providence Research**

1081 Burrard St, Vancouver, BC, V6Z 1Y6,  
604-806-9464 providenceresearch.ca

**Research Universities Council of British Columbia**

Suite 400-880 Douglas Street,  
Victoria, BC, V8W 2B7,  
250-480-4859 rucbc.ca

**Simon Fraser University - Beedie School of Business**

8888 University Drive, Burnaby, BC, V5A 1S6,  
778-782-5567 beedie.sfu.ca

**Simon Fraser University - Faculty of Science**

8888 University Drive, Burnaby, BC, V5A 1S6,  
778-782-4590 sfu.ca

**St. Paul's Foundation**

1081 Burrard Street 178,  
Vancouver, BC, V6Z 1Y6,  
604-682-8206 helpstpauls.com

**Sustained Therapeutics**

2660 Oak Street, Vancouver, BC, V6H 3Z6,

**TRIUMF Innovations**

4004 Westbrook Mall., Vancouver, BC, V6T 2A3,  
604-222-1047 triumphinnovations.ca

**UBC Faculty of Medicine - Academy of Translational Medicine**

307 - 2194 Health Sciences Mall, Vancouver, BC,  
V6T 2B9, atm.med.ubc.ca

**University of British Columbia - Faculty of Medicine**

317 - 2194 Health Sciences Mall,  
Vancouver, BC, V6T 1Z3,  
604-822-2421 med.ubc.ca

**University of British Columbia - Faculty of Pharmaceutical Sciences**

3309-2405 Westbrook Mall, Vancouver, BC, V6T  
1Z3, pharmsci.ubc.ca

**University of British Columbia - School of Biomedical Engineering**

2222 Health Sciences Mall, Vancouver, BC,  
V6T1Z3 Canada, Vancouver, BC, V6T1Z3,  
604-822-7810 bme.ubc.ca

**Vancouver Coastal Health Research Institute (VCHRI)**

2635 Laurel Street, 6th Floor,  
Vancouver, BC, V5Z 1M9,  
604-875-4372 vchri.ca

## ASSOCIATIONS &amp; GOVERNMENT

**Australian Consulate & Trade Commission**

175 Bloor St E, South Tower, Suite 1100,  
Toronto, ON, M4W 3R8,  
416-323-4284 austrade.gov.au

**BC Tech Association**

210-1401 W 8th Ave, Vancouver, BC, V6H 1C9,  
604-683-6159 wearebctech.com

**BioTalent Canada**

650-130 Slater Street, Ottawa, ON, K1P 6E2,  
866-243-2472 biotalent.ca

**BIOTECANADA**

600-1 Nicholas Street,  
Ottawa, Ontario, K1N 7B7,  
613-230-5585 biotech.ca

**Digital Supercluster**

2000 - 800 Robson Street, Vancouver, BC, V6Z  
2E7, digitalsupercluster.ca

**Embassy of the Republic of Lithuania to Canada**

1600-150 Metcalfe str., Ottawa, ON, K2P 1P1,  
613-567-5458 ca.mfa.lt

**Gairdner Foundation**

MaRS Centre, Heritage Building, 101 College  
Street, Suite 335, Toronto, ON, M5G 1L7,  
416-596-9996 gairdner.org

**Innovative Medicines Canada**

55 Metcalfe Street, Ottawa, ON, K1P 6L5,  
613-236-0455 innovativemedicines.ca

**Ministry of Jobs, Economic Recovery and Innovation**

501 Belleville Street, Victoria, BC, V8V 1X4,  
604-660-2421 britishcolumbia.ca

**National Research Council Canada**

1185 West Georgia Street Suite 650,  
Vancouver, BC, V6E 4E6,  
604-221-3000 nrc-cnrc.gc.ca

## BUSINESS CONSULTANTS

**British Columbia Securities Commission**

701 West Georgia Street, P.O. Box 10142, Pacific  
Centre, Vancouver, BC, V7Y 1L2,  
604-899-6854 bcsc.bc.ca

**Cagley Johnson Consulting Inc.**

302-608 Broughton Street,  
Victoria, BC, V8W 1C7,  
250-516-3153 cagleyjohnson.com

**Chinook Contract Research Inc.**

381 Montcalm Ave,  
Victoria, BC, V8Z 6R3,  
403-714-7922 ccr01.com

**Evonik Health Care**

8855 Northbrook, Burnaby, BC, V5J  
5J1, healthcare.evonik.com

**EY**

1066 W Hastings St., Suite 2300,  
Vancouver, BC, V6E 3X2,  
ey.com

**Grantek**

11331 Coppersmith Way, Suite 310,  
Richmond, BC, V7A 5J9,  
866-936-9509 grantek.com

**Kirke Management Consulting**

PO Box 224, Vancouver, BC, V6N 2E0,  
604-787-3230 kirke-consulting.com

**Metamor Health**

647-501-8826 metamorhealth.com

**Metaphase Health Research Consulting, Inc.**

1879 Knox Road, Vancouver, BC, V6T 1S4,  
604-224-5925 metaphase-consulting.com

**MYND Life Sciences**

719 Finns Road, Kelowna,  
BC, V1X 5B7,  
403-559-6779 myndsciences.com

**Omega Laboratories Inc**

110-42 Fawcett Rd, Coquitlam, BC, V3K 6X9,  
604-554-1228 omegalaboratories.com

**Paragon Ventures Inc**

2nd Floor, 555 Burrard Street,  
Vancouver, BC, V7X 1M8,  
604-805-7071 paragonventures.com

**Pender & Howe Executive Search**

Suite 810, 1040 West Georgia St,  
Vancouver, BC, V6E 4H1,  
780-232-0929 penderhowe.com

**PharmaBioSource**

Victoria, BC, 610-293-0900  
pharmabiosource.com

**Stratesol Consulting**

3496 Marine Drive,  
West Vancouver, BC, V7V 1N2,  
604-506-6617 stratesol.com

**Third Quarter Consulting Group**

13252 17a Ave, Surrey, BC, V4A 6R9,  
888-703-3006

**WestPAR Consultancy Inc.**

600 - 1285 West Broadway,  
Vancouver, BC, V6H 3X8,  
604-319-9949 westpar.ca

**World Courier, an AmerisourceBergen company**

Suite 170, 3751 Shell Road,  
Richmond, BC, V6X 2V2,  
604-232-9444 worldcourier.com

## CONTRACT RESEARCH &amp; SCIENTIFIC SERVICES

**American Preclinical Services (APS)**

8945 Evergreen Blvd NW,  
Minneapolis, MN, 55433,  
877-717-7997 americanpreclinical.com

**BC Academic Health Science Network / Clinical Trials BC**

Suite - 420 - 1367 West Broadway,  
Vancouver, BC, V6H 4A7,  
236-521-2064 bcahsn.ca

**BioBoost Synbio Consulting Inc**

3160-853 Seaborne ave,  
Port Coquitlam, BC, V3B 0N9,  
604-356-6676 bioboostsynbio.com

**Brevisretero Corporation**

9688 Regional Road 25,  
Milton, ON, L9T 2X7,  
416-417-7675 brevisretero.com

**BRI Biopharmaceutical Research Inc.**

101 - 8898 Heather Street,  
Vancouver, BC, V6P 3S8,  
604-432-9237 bripharm.com

**Brigene Biosciences Inc.**

421-3800 Westbrook Mall,  
Vancouver, BC, V6S 2L9,  
604-767-6155 ubrigene.com

**CEQAL Inc.**

307 - 2083 Alma Street,  
Vancouver, BC, V6R 4N6,  
877-265-7024 ceqal.com

**Cytiva**

250 Howe Street, Suite 1400-C,  
Vancouver, BC, V6C 3S7,  
800-463-5800 cytivalifesciences.com

**EMMES Canada**

200-4664 Lougheed Highway,  
Burnaby, BC, V5C 5T5,  
778-806-4626 emmes.ca

**Groupe PARIMA Inc.**

4450, Cousins, Montreal, QC, H4S 1X6,  
514-338-3780 groupeparima.com

**HTuO Biosciences Inc.**

400-610 Main St, Vancouver, BC, V6A  
2V3, htubio.com

**IonsGate Preclinical Services Inc.**

222-2176 Health Sciences Mall,  
Vancouver, BC, V6T1Z3,  
604-827-1733 ionsgate.com

**L9 BioScience Inc.**

13564 Crestview Drive, Surrey, BC, V3R 6T2,  
L9bioscience.com

**Microbiome Insights Inc.**

2950 Talmie Street, Vancouver, BC, V6R 4K6,  
604-356-4228 microbiomeinsights.com

**Molecular Forecaster Inc.**

7171 Rue Frederick Banting, Montreal, QC,  
H4S1Z9, molecularforecaster.com

**Novateur Ventures Inc.**

1055 West Georgia Street, Suite 2100,  
Vancouver, BC, V6E 3P3,  
844-200-6682 novateur.ca

**Numinus Wellness Inc.**

801 - 33 Water Street, Vancouver, BC, V6B 1R4,  
833-686-4687 numinus.com

**Pharma Inventor Inc.**

3800 Westbrook Mall, Suite 202- 215,  
Vancouver, BC, V6S 2L9,  
604-339-3244 pharmainventor.com

**PharmaDirections, Inc.**

15100 Weston Parkway, Suite 101,  
Cary, NC, 27513,  
919-657-0660 PharmaDirections.com

**Phyton Biotech LLC**

1503 Cliveden Avenue, Delta, BC, V3M 6P7,  
604-777-2340 phytonbiotech.com

**Platform LifeSciences**

506-1505 W 2nd Ave, Vancouver, BC, V6H 3Y4,  
604-731-0688 platformlifesciences.com

**Precision NanoSystems Inc.**

50 - 655 West Kent Ave,  
Vancouver, BC, V6P 6T7,  
888-618-0031 precisionnanosystems.com

**Prime Site Research Solutions Inc.**

7508 Getty Gate, Suite 217,  
Edmonton, AB, T5T 7E6,  
888-600-1999 primesiteresearch.com

**SignalChem Lifesciences Corp.**

110 - 13120, Vanier Place,  
Richmond, BC, V6V 2J2,  
604-232-4600 signalchemlifesciences.com

**Zifo RND Solutions**

7111 Syntax Drive, Mississauga, ON, L5N  
8C3, ziford.com

## DIAGNOSTICS

**Augurex**

220- 887 Great Northern Way,  
Vancouver, BC, V5T 4T5,  
604-637-3280 augurex.com

**Gemina Laboratories**

3800 Westbrook Mall, Suite 142, Vancouver, BC,  
V6T 1W5, geminalabs.com

**Izotropic Corporation**

Suite 424, 800-15355 24th Avenue,  
Surrey, BC, V4A 2H9,  
833-496-2677 izocorp.com

**Lifelabs**

3680 Gilmore Way, Burnaby, BC, V5G 4V8,  
604-431-7206 lifelabs.com

**Onestep Laboratories Inc.**

162-628 E Kent Ave S, Vancouver, BC, V5X0B2,  
778-985-1242 1steplab.com

## DIGITAL HEALTH

**Brighton Group Health Industry Solutions**

W23rd, Vancouver, BC, ,  
416-414-6957 brightongrouphealth.com

**Canary Medical Inc**

1450 Creekside Dr., Suite 400, Vancouver, BC,  
V6J 5B3, canarymedical.com



## LIFE SCIENCES BC MEMBERSHIP DIRECTORY

**HealthQB**

6163 University Blvd, Vancouver, BC,  
yourhealthqb.com

**Molecular You**

788 Beatty Street, Suite 307,  
Vancouver, BC, V6B 2M1,  
800-380-1468 molecularyou.com

**PantRidgeDeLL Health Technologies CORP.**

750 Jervis Street, Unit 1202,  
Vancouver, BC, V6E 0B4,  
778-237-9269

**PHEMI Systems Corporation**

600, 777 Hornby Street,  
Vancouver, BC, V6Z 1S4,  
800-841-1609 phemi.com

**Thrive Health**

116 W Hastings St Suite 200,  
Vancouver, BC, V6B 1G8,  
604-200-6431 thrive.health

**VWR International Ltd. (Avantor)**

2360 Argentia Rd, Mississauga, ON, L5N5Z7,  
514-298-5133 ca.vwr.com

**XCO Tech Inc**

129 Nanaimo Ave W, Penticton, BC, V2A  
1N2, xco.io

## FACILITIES &amp; REAL ESTATE

**Chernoff Thompson Architects**

1340 - 1075 West Georgia Street,  
Vancouver, BC, V6E 3C9,  
604-668-9460 cta.bc.ca

**HDR**

500-1500 West Georgia Street,  
Vancouver, BC, V6G 2Z6,  
604-687-1898 hdrinc.com

**Health and Technology District**

1500-13737 96th Ave, Surrey, BC, V3V 0C6,  
healthandtechnologydistrict.com

**Jerzy's Corner**

1101 Union Street, Vancouver, BC, V6A 2C7,  
604-692-1472 jerzyscorner.com

**Novacom Building Partners**

101-18663 52nd Avenue,  
Surrey, BC, V3S 8E5,  
604-273-7303 novacom.ca

**Porte Communities**

100-33 East 8th Avenue,  
Vancouver, BC, V5T 1R5,  
604-732-7651 porte.ca

**The High Technology Facilities Group at CBRE Ltd.**

2500 - 1021 West Hastings Street,  
Vancouver, BC, V6E 0C3,  
604-662-3000 hightech.cbrevancouver.com

**Wales McLelland Construction**

6211 Fraserwood Place,  
Richmond, BC, V6W 1J2,  
604-638-1212 walesmcllelland.com

## FINANCIAL &amp; INSURANCE SERVICES

**AON**

1200-401 West Georgia Street,  
Vancouver, BC, V6B 5A1,  
604-727-3105 aon.ca

**Axis**

400-555 Burrard Street,  
Vancouver, BC, V7X 1M8,  
604-731-5328 axisinsurance.ca

**Beazley Group**

906-1021 West Hastings Street,  
Vancouver, BC, V6E 0C3,  
778-373-4432 beazley.com

**Berkley Canada**

145 King Street W. Suite 1000,  
Toronto, ON, M5H 1J8,  
647-286-3708 berkleycanada.com

**Deloitte LLP**

2800-1055 Dunsmuir Street,  
Vancouver, BC, V7X 1P4,  
604-669-4466 www.deloitte.com

**KPMG LLP**

777 Dunsmuir Street, Vancouver, BC, V7Y 1K3,  
604-691-3000 kpmg.ca

**PwC LLP**

250 Howe Street, Suite 1400,  
Vancouver, BC, V6C 3S7,  
604-806-7000 pwc.com

## GENOMICS

**Canexia Health**

Suite 204 2389 Health Sciences Mall,  
Vancouver, BC, V6T 1Z3,  
778-379-2931 canexiahealth.com

**Discovery DNA Inc.**

2201 W Broadway,  
Vancouver, British Columbia, V6K 2E4,  
403-629-7212 discoverydna.ca

**Fusion Genomics Corporation**

Discovery 1 1450, 8888 University Drive,  
Burnaby, BC, V5A 1S6,  
604-428-7701 fusiongenomics.com

**Incisive Genetics Inc.**

301 - 980 George Street,  
Vancouver, BC, V6A 0H9,  
604-409-0660 incisivegenetics.com

## GLOBAL PHARMACEUTICAL CORPORATION

**AbbVie Corporation**

8401 Trans-Canada Highway,  
Saint-Laurent, QC, H4S 1Z1,  
888-703-3006 abbvie.ca

**Amgen British Columbia**

7900 Enterprise Street, Burnaby, BC, V5A 1V7,  
604-415-1800 amgen.ca

**AstraZeneca Canada Inc.**

1004 Middlegate Road,  
Mississauga, ON, L4Y 1M4,  
800-565-5877 astrazeneca.ca

**Bausch Health**

2150 boul. St-Elzar Ouest,  
Laval, Quebec, H7L 4A8,  
800-361-1448 bauschhealth.ca

**BeiGene Canada**

2425 Matheson BLVD E, 8th Floor,  
Mississauga, ON, L4W 5K4,  
647-496-7420 beigene.com

**Boehringer Ingelheim**

5180 South Service Road,  
Burlington, ON, L7L 5H4,  
905-639-0333 boehringer-ingelheim.ca

**EMD Serono**

200-2695 North Sheridan Way,  
Mississauga, ON, L5K 2N6,  
604-353-8356 emdserono.ca

**Gilead Sciences Inc.**

6711 Mississauga Rd Suite 600,  
Mississauga, ON, L5N 2W3,  
905-363-8008 gilead.com

**Glaxosmithkline Inc. / GSK**

7333 Mississauga Road,  
Mississauga, ON, L5N 6L4,  
905-819-3000 ca.gsk.com

**Hoffmann-La Roche Ltd.**

7070 Mississauga Road,  
Mississauga, ON, L5N 5M8,  
905-542-7130 rochecanada.com

**Horizon Therapeutics Canada**

9131 Keele Street, Unit 4A,  
Vaughan, ON, L4K 0G7,  
866-479-6742 horizontherapeutics.ca

**Janssen Inc.**

19 Green Belt Dr., Toronto, ON, M3C 1L9,  
416-449-9444 janssen.ca

**Merck Canada Inc.**

16750 Trans-Canada Hwy.,  
Kirkland, QC, H9H 4M7,  
514-422-8600 merck.ca

**Novartis Pharmaceuticals Canada Inc.**

385 Bouchard Blvd, Dorval, QC, H9S 1A9,  
514-631-6775 novartis.ca

**Novo Nordisk Canada Inc.**

101-2476 Argentia Road,  
Mississauga, ON, L5N 6M1,  
800-465-4334 novonordisk.ca

**Pfizer Canada Inc.**

17300 Trans-Canada Highway,  
Kirkland, QC, H9J 2M5,  
877-633-2001 pfizer.ca

**Q&C Services**

2000 Argentia Road, Plaza 2, Suite 220,  
Mississauga, ON, L5N 1V8,  
905-363-1182 qualityandcompliance.com

**Sanofi Canada**

2905 Place Louis-R-Renaud,  
Laval, QC, H7V 0A3,  
800-265-7927 sanofi.ca

**Takeda Canada Inc.**

Bay Adelaide Centre, 22 Adelaide St W Suite  
3800, Toronto, ON, M5H 4E3,  
866-397-4473 takedacanada.com

**Willow Biosciences**

Suite 200, 2250 Boundary Road,  
Burnaby, BC, V5M3Z3,  
236-471-5341 willowbio.com

## INVESTORS

**Amplitude Ventures**

Espace CDPQ: 3 Place Ville Marie, Suite 12350,  
Montreal, QC, H3B 0E7,  
514-298-4222 amplitudevc.com

**Institute of Health Economics (IHE)**

1200, 10405 Jasper Avenue,  
Edmonton, AB, T5J 3N4,  
780-448-4881 ihe.ca

**Libang Capital (Canada) Limited**

Unit 175, 2639 Viking Way,  
Richmond, BC, V6V 3B7,  
604-821-1141 libangcapital.ca

**Lumira Ventures**

141 Adelaide Street West,  
Toronto, ON, M5H 3L5,  
604-558-5156 lumiraventures.com

**Nimbus Synergies**

400-610 Main St., Vancouver, BC, V6A 2V3,  
604-734-7275 nimbusinc.vc

**Northview LifeSciences**

2820 - 200 Granville Street,  
Vancouver, BC, V6C 1S4,  
604-428-4641 northviewlifesciences.com

**Quark Venture LP**

Suite 2500, 1075 West Georgia Street,  
Vancouver, BC, V6E 3C9,  
604-262-8818 quarkventure.com

**Silicon Valley Bank**

4410-161 Bay Street, Toronto, ON, M5J 2S1,  
416-417-7888 svb.com

## LEGAL SERVICES

**Arazy Group Consultants Inc.**

Pier 32 Granville Island, 200-1333 Johnston  
Street, Vancouver, BC, V6H 3R9,  
604-681-6888 arazygroup.com

**Blake, Cassels & Graydon LLP**

595 Burrard Street, P.O. Box 49314,  
Vancouver, BC,  
604-631-3300 blakes.com



CHRISTENSEN | O'CONNOR  
JOHNSON | KINDNESS

**Christensen O'Connor Johnson Kindness PLLC**

1201 Third Avenue, Suite 3600,  
Seattle, WA, 98101,  
206-682-8100 cojk.com

**DigbyGlobal**

4278 12th Ave W, Vancouver, BC, V6R 2P7,  
604-362-9019 digbyglobal.com

**Farris LLP**

PO Box 10026, Pacific Centre South,  
Vancouver, BC, V7Y 1B3,  
604-684-9151 farris.com

**Fasken LLP**

Bentall 5, 2900 - 550 Burrard Street,  
Vancouver, BC, V6C 0A3,  
604-631-3131 fasken.com

**Gowling WLG (Canada) LLP**

2300 - 550 Burrard St., Vancouver, BC, V6C 2B5,  
604-683-6498 gowlingwlg.com

**McCarthy Tetrault LLP**

745 Thurlow St. 2400, Vancouver, BC, V6E 0C5,  
604-643-7100 mccarthy.ca

**Norton Rose Fulbright Canada LLP**

1800-510 West Georgia Street,  
Vancouver, BC, V6B 0M3,  
604-687-6575 nortonrosefulbright.com

**Osler, Hoskin & Harcourt LLP**

Suite 1700, Guinness Tower, 1055 W Hastings  
St., Vancouver, BC, V6E 2E9,  
778-785-3000 osler.com

**Oyen Wiggs Green & Mutala LLP**

480, The Station 601 West Cordova Street,  
Vancouver, BC, V6B 1G1,  
604-669-3432 patentable.com

**Seed Intellectual Property Law Group LLP**

701 Fifth Avenue, Suite 5400,  
Seattle, WA, 98104,  
206-622-4900 SeedIP.com

## MEDIA &amp; COMMUNICATIONS

**biofilm MEDIA**

7398 Capistrano Dr., Unit bf,  
Burnaby, BC, V5A1P8,  
604-724-3233 biofilmmedia.com

**Coast Communications and Public Affairs**

1526 Duranleau Street, Vancouver, BC, V6H 3S4,  
604-767-0207 coastcomms.ca

**Reboot Communications Ltd.**

814-21 Dallas Road, Victoria, BC, V8V 4Z9,  
250-388-6060 rebootcommunications.com

## MEDICAL DEVICE

**Artron BioResearch Inc.**

3938 North Fraser Way, Burnaby, BC, V5J 5H6,  
604-415-9757 artronbio.com

**bioLytical Laboratories Inc.**

13251 Delf Pl Unit 406, Richmond, BC, V6V 2A2,  
604-204-6784 biolytical.com

**Corcym Canada Corp.**

5005 North Fraser Way,  
Burnaby, BC, V5J 5M1,  
604-412-5650 corcym.com

**DP Labs and Biotechnology Inc.**

Victoria, BC, dplabs.ca

**Electromate Inc.**

6221 Highway 7, Unit 15,  
Vaughan, ON, L4H 0K8,  
877-737-8698 electromate.com

**eSensio Biotech Inc.**

205-3855 Henning Dr., Burnaby, BC, V5C 6N3,  
778-655-1016 esensotech.com

**Farabloc Development Corp.**

2 - 8330 Young Road, Chilliwack, BC, V2P 4N8,  
604-941-8201 farabloc.com

**Gene Bio Medical**

540-6388 No. 3 Road, Richmond, BC, V6Y 2B3,  
604-370-0166 genebiomedical.com

**GuideStar Medical Devices**

201-2067 Cadboro Bay Road,  
Victoria, BC, V8R 5G4,  
250-940-0017 guidestarmd.com

**IKOMED Technologies Inc.**

1375 McLean Drive, Vancouver, BC, V5L 3N7,  
604-258-0028 ikomed.com

**InnoTech Medical Industries Corp.**

124 Garden Ave, North Vancouver, BC, V7P 3H2,  
800-756-4204 imixray.com

**Innovatek Medical Inc.**

3 - 1600 Derwent Way, Delta, BC, V3M 6M5,  
604-522-8303 innovatekmed.com

**Kardium Inc.**

155 - 8518 Glenlyon Parkway,  
Burnaby, BC, V5J 0B6,  
604-248-8891 kardium.com

**Libang Surgical Technologies**

Suite 202, 50 Fell Ave,  
North Vancouver, BC, V7P 3S2,  
604-285-9975 libangsurgical.com

**NZ Technologies Inc.**

202-1401 West Broadway,  
Vancouver, BC, V6H 1H6,  
604-336-9464 nztech.ca

**ORX Surgical**

12460 Vickers Way, Richmond, BC, V6V 1H9,  
orx.ai

**Response Biomedical Corp.**

1781 - 75th Avenue W., Vancouver, BC, V6P 6P2,  
604-456-6010 responsebio.com

**Rostrum Medical Innovations Inc.**

3687 East 1st Avenue, Vancouver, BC, V5M 1C2,  
604-439-3054 rostrummedical.com

**StarFish Medical**

455 Boleskine Road, Victoria, BC, V8Z 1E7,  
250-388-3537 starfishmedical.com

**MEDICAL TECHNOLOGY****3DQue Systems Inc.**

45-1146 Pacific Blvd, Vancouver, BC, V6Z 2X7,  
604-755-7162 3dque.com

**ABOzymes Biomedical Inc.**

1101-1025 Gifford Street, Vancouver, BC, ,  
604-831-8334 abozymes.com

**Acuitas Therapeutics**

6190 Agronomy Road, Suite 405, University of  
British Columbia, Vancouver, BC, V6T 1Z3,  
604-227-3904 acuitasx.com

**Aspect Biosystems**

1781 West 75th Avenue,  
Vancouver, BC, V6P 6P2,  
604-263-0502 aspectbiosystems.com

**Axolotl Biosciences**

3800 Finnerty Road,  
Victoria, BC, V8W 2Y2,  
250-858-0534 axolotlbiosciences.com

**Claris Healthcare**

201-1099 West 8th Ave,  
Vancouver, BC, V6H 1C3,  
604-828-9789 clarishealthcare.com

**Manzanita Pharmaceuticals, Inc.**

2995 Woodside RD, Suite 400, PMB 380,  
Woodside, California, 94062,  
408-348-3191 manzanitapharmaceuticals.com

**ScopeSys Inc.**

33 Rue Prince, Montreal, QC, H3C 2M7,  
519-820-3450 scopesys.ca

**Sonic Incytes Medical Corp.**

560-828 West 10th Avenue,  
Vancouver, BC, V5Z 1M9,  
800-881-0096 sonicincytes.com

**Sonus Microsystems**

2332 Main Mall, University of British Columbia,  
Vancouver, BC, V5Y 2C4,  
604-822-2045 sonusmicrosystems.com

**Tel-Array Diagnostics Inc.**

418-3800 Westbrook Mall,  
Vancouver, BC, V6S 2L9,  
604-221-9227 telarray.com

**Variational AI**

201-577 Great Northern Way,  
Vancouver, BC, V5T 1E1,  
604-761-7199 variational.ai

**VoxCell BioInnovation**

305 - 21 Gorge Road East, Victoria, BC, V9A 0C6,  
778-587-9955 voxcellbio.com

**SCIENTIFIC SUPPLIES****Alliance Scientific**

106 - 19298 - 21 Avenue, Surrey, BC, V3Z 3M3,  
800-375-2213 alliancescientific.net

**SCIEX**

71 Four Valley Drive, Vaughan, ON, L4K 4V8,  
403-990-0562 sciex.com

**STEMCELL Technologies Canada Inc.**

570 West Seventh Avenue, Suite 400,  
Vancouver, BC, V5Z 1B3,  
604-877-0713 stemcell.com

**StressMarq Biosciences Inc.**

117-1537 Hillside Avenue, Victoria, BC, V8T 2C1,  
250-294-9065 stressmarq.com

**THERAPEUTICS****4M BioTech**

Suite 200, 535 Yates Street,  
Victoria, BC, V8W 2Z6, 4mbiotech.com

**AbCellera**

2215 Yukon Street, Vancouver, BC, V5Y 0A1,  
604-559-9005 abcellera.com

**Abdera Therapeutics**

2405 Wesbrook Mall, 4th Floor,  
Vancouver, BC, V6T 1Z3,  
604-827-1147 abderatherapeutics.com

**Aequus Pharmaceuticals**

2820 - 200 Granville Street,  
Vancouver, BC, V6C 1S4,  
604-336-7906 aequuspharma.ca

**Alectos Therapeutics**

8999 Nelson Way, Burnaby, BC, V5A 4B5,  
604-628-7129 alectos.com

**Algernon Pharmaceuticals**

400-601 West Broadway, Vancouver, BC, V5Z  
4C2, algernonpharmaceuticals.com

**Alpha-9 Theranostics**

27 East 7th Ave, Vancouver, BC, V5T  
1M4, alpha9tx.com

**Apricell Biotechnology Inc.**

307-1900 Watkiss Way,  
Victoria, BC, V9P 6N1, apricell.com

**ARC Medical Devices, Inc.**

Unit 8 - 3071 No. 5 Road,  
Richmond, BC, V6X 2T4,  
604-222-9577 arcmedicaldevices.com

**ARTMS**

Suite 301 - 4475 Wayburne Drive,  
Burnaby, BC, V5G 4X4,  
604-228-4016 artms.ca

**Aurinia Pharma U.S., Inc.**

1203-4464 Markham Street,  
Victoria, BC, V8Z 7X8,  
250-744-2487 auriniapharma.com

**Aurora BioSolutions Inc.**

PO Box 21053 Crescent Heights PO,  
Medicine Hat, AB, T1A 6N0,  
403-928-8503 aurorabiosolutions.com

**Azor Biotech**

Victoria, BC, 250-899-8305 azorbiotech.ca

**Bioasis Technologies Inc.**

157 Church Street, 19th Floor, New Haven,  
Connecticut, 06510,  
203-533-7082 bioasis.us

**Bold Therapeutics Inc.**

515 - 850 W. Hastings Street,  
Vancouver, BC, V6C1E1,  
604-262-9959 bold-therapeutics.com

**Boreal Genomics Inc.**

2386 East Mall, Suite 300,  
Vancouver, BC, V6T 1Z3,  
604-822-8268 borealgenomics.com

**Celgene Inc.**

6755 Mississauga Rd., Suite 600,  
Mississauga, ON, L5N 7Y2,  
877-923-5436 celgene.ca

**Chinook Therapeutics Inc.**

210-887 Great Northern Way,  
Vancouver, BC, V5T 4T5, chinooktx.com

**Clairvoyant Therapeutics Inc.**

2400 1055 W Georgia Street,  
Vancouver, BC, V6E 3P3,  
778-747-3989 clairvoyantrx.com

**Cureimmune Therapeutics Inc.**

8755 Ash Street, Suite 2,  
Vancouver, BC, V6P 6T3,  
778-379-6883 cureimmune.com

**Delta-Fly Pharma Inc.**

801-1080 Howe Street, Vancouver, BC, V6Z  
2T1, delta-flypharma.co.jp

**Derm-Biome Pharmaceuticals Inc**

1201 638 Beach Crescent,  
Vancouver, BC, V6Z 3H4,  
604-220-8700 derm-biomepharmaceuticals.com

**Domain Therapeutics NA Inc.**

7171 Frederick-Banting,  
Saint-Laurent, QC, H4S 1Z9,  
438-403-7099 domaintherapeutics.ca

**Dr. Ma's Laboratories**

4-8118 North Fraser Way,  
Burnaby, BC, V5J 0E5,  
604-439-6089 drmalabs.com

**ESSA Pharma Inc.**

Suite 720, 999 West Broadway,  
Vancouver, BC, V5Z 1K5,  
778-331-0962 essapharma.com

**Eupraxia Pharmaceuticals Inc.**

201-2067 Cadboro Bay Road,  
Victoria, BC, V8R 5G4,  
250-590-3968 eupraxiapharmaceuticals.com

**Gandeeva Therapeutics**

3885 Henning Drive, Burnaby, BC, V5C 6N5,  
778-731-1022 gandeeva.com

**Genevant Sciences, Corp.**

155-877 Great Northern Way,  
Vancouver, BC, V5T 4T5,  
778-800-2363 genevant.com

**Hamilton Company**

4970 Energy Way Reno, NV 89502 U.S.A.,  
775-858-3000 hamiltoncompany.com

**InMed Pharmaceuticals Inc.**

Suite 310-815 West Hastings St.,  
Vancouver, BC, V6C1B4,  
604-669-7207 inmedpharma.com

**Innovative Targeting Solutions Inc.**

290-2985 Virtual Way, Vancouver, BC, V5M 4X7,  
604-433-6779 innovativetargeting.com

**Integrated Nanotherapeutics Inc.**

Suite 205, 4475 Wayburne Drive,  
Burnaby, BC, V5G 4X4,  
778-819-1622 integratedntx.com

**iProgen Biotech Inc.**

8531 Commerce Crt, Burnaby, BC, V5A 4N4,  
604-428-4978 iprogen.com

**IRICoR**

C.P. 6128, Downtown station,  
Montreal, QC, H3C 3J7,  
514-343-6111 iricor.ca

**Kapoose Creek Wellness**

Kapoose Creek, BC, kapoosecreekwellness.com

**Kintara Therapeutics**

720 - 999 West Broadway,  
Vancouver, BC, V5Z 1K5,  
858-350-4364 kintara.com

**LAST Innovations Ltd.**

Suite 990 - 777 Hornby Street,  
Vancouver, BC, V6Z1S4,  
604-622-5250

**Me Therapeutics Inc.**

5520 - 2350 Health Sciences Mall,  
Vancouver, BC, V6T 1Z3, metherapeutics.com

**Mesentech**

2222 Health Sciences Mall,  
Vancouver, BC, V6T 1Z3,  
774-234-8018 mesentech.com

**Mesintel Therapeutics Inc.**

510 West Georgia Street, Suite 1800,  
Vancouver, BC, mesintel.com

**Microbion Pharma Corp.**

406-233-6472 microbioncorp.com

**NanoVation Therapeutics**

2045 Westbrook Mall 4th floor, Vancouver, BC,  
V6T 1Z3, nanovationtx.com

**NervGen Pharma Corp.**

2955 Virtual Way, Suite 480,  
Vancouver, BC, V5M 4X6,  
778-731-1711 nervgen.com

**New Beta Innovation Canada Limited**

168 - 8508 Glenlyon Parkway,  
Burnaby, BC, V5J 0B6,  
604-421-7308 newbetainnovation.ca

**Notch Therapeutics, Inc.**

500-887 Great Northern Way, Vancouver, BC,  
V5T 4T5,  
604-449-6662 notchtx.com

**Oak Bay Biosciences**

Virtual, Victoria, BC, ,  
250-886-1849 oakbaybio.com

**Ondine Biomedical Inc.**

888 - 1100 Melville Street, Vancouver, BC,  
V6E 4A6,  
604-669-0555 ondinebio.com

**Pramana Pharmaceuticals Inc.**

602-570 Granville Street,  
Vancouver, BC, V6C 3P1,  
604-721-1710 pramanapharma.ca

**Primary Peptides Inc.**

Unit F168, 2211 Wesbrook Mall, Vancouver, BC,  
V6T 2B5,  
236-518-7538 primarypeptides.com

**Qu Biologics Inc.**

4475 Wayburne Drive, Suite 305, Burnaby, BC,  
V5G 4X4,  
604-734-1450 qubiologics.com

**RepliCel Life Sciences Inc.**

Suite 900 - 570 Granville Street, Vancouver, BC,  
V6C 3P1,  
604-248-8730 replicel.com

**Resilience Biosciences Inc.**

2402 Wesbrook Mall, 4th Floor,  
Vancouver, BC, V6T 1Z3,  
resiliencebiosciences.com

**Sernova Corp**

700 Collip Circle, Ste 114, London, ON, N6G 4X8,  
519-858-5184 sernova.com

**Shackelford Pharma Inc.**

P.O. Box 10026 Pacific Centre South, 25th Floor,  
700 W. Georgia Street., Vancouver, BC, V7Y1B3,  
888-377-4225 shackelfordpharma.com

**Symvivo Corporation**

8900 Glenlyon Parkway, Burnaby, BC, V5J5J8,  
604-428-7474 symvivo.com

**Virogin Biotech Canada Ltd.**

408-3800 Westbrook Mall, Vancouver, BC, V6S  
2L9,  
604-222-0591 virogin.com

**WEX Pharmaceuticals Inc.**

1150-1100 Melville Street, Vancouver, BC,  
V6E 4A6,  
604-683-8880 wextech.ca

**Xenon Pharmaceuticals Inc.**


200 - 3650 Gilmore Way, Burnaby, BC, V5G 4W8,  
604-484-3300 xenon-pharma.com

**Zucara Therapeutics Inc.**

661 University Avenue, Suite 1300,  
Toronto, ON, M5G 0B7,  
416-859-3978 zucara.ca

**Zymeworks Inc.**

800 - 114 East Fourth Avenue,  
Vancouver, BC, V6T 1G4,  
604-678-1388 zymeworks.com



Next generation of clinical trials.

[platformlifesciences.com](https://platformlifesciences.com)